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 The American Heart Association estimates that congestive heart failure (CHF) 
affects over 5 million people in the United States.  Recent research indicates that current 
pharmacological therapies have limitations in their ability to treat end-stage heart failure 
patients.  Device based therapies that provide passive support and active assist through 
altering the stress environment to reduce end diastolic volume and increase stroke work 
may be beneficial in overcoming the limitations of simply just increasing the use of 
pharmacological therapies; however, current devices are inadequate in their design to 
restore natural heart mechanics.  Dr. John C. Criscione of Texas A&M has proposed a 
minimally invasive adjustable active cardiac support device (AACSD) that promotes 
natural heart mechanics using passive support and active assist.  Design research, using 
FDA Design Controls, is necessary to supplement prototyping to develop and embody a 
design for manufacture for continued proof-of-concept studies in ovines. 
 The design research consists of identifying user needs and functionality of the 
AACSD for the development of design specifications that drive the design process for 
the selection of a suitable concept for the AACSD.  With a concept selected, geometry 
and materials of the device are selected to embody a design for manufacture.  A parts 
list, engineering drawings, and assembly instructions allow for the manufacture of the 
device.  Finally, a failure modes and effects analysis allows for evaluation of the design 
and recommendations for future design research.  The design research successfully 
identified an embodied design for manufacture that will aid in further development of 
the AACSD as a future therapy for CHF.  
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Congestive heart failure (CHF) is a serious disease widely prevalent in society.  
In 2005, CHF affected approximately 5,300,000 adults over the age of 20, and 
contributed to 284,365 deaths (AHA, 2008).  The estimated costs due to CHF in the 
United States for 2008 are $34.8 billion, with $31.7 billion coming from direct costs of 
hospitals, nursing homes, physicians, and drugs (AHA, 2008).   
In CHF, the heart undergoes changes on the anatomical, cellular, molecular, and 
genetic scales (Scoote et al., 2006).  Anatomical response is present in the form of 
cardiac remodeling, which results in dilatation of the heart.  The dilated heart is 
associated with increased ventricular geometry towards a more spherical shape and 
reduced ventricular wall thickness, which adversely affects cardiac function (Scoote et 
al., 2006).  The cardiac output (CO) of the heart is a function of the stretch, or preload, 
of the muscle fibers before contraction.  This stretch is a function of end diastolic 
pressure (EDP).   In response to reduced CO, the heart‟s intrinsic response is to increase 
the preloading of the fibers.  In normal operation of non-failing hearts, this increased 
preloading results in increased contractility and increased CO; this is known as the 
Frank-Starling Law and can be seen in the normal heart curve in Fig. 1 (Nicholson, 
2007).   
The elevated EDP affects the geometry of the left ventricle.  As EDP rises, 
increased pressure is placed on the ventricular wall, resulting in distention of the 
ventricle and an increase end diastolic volume (EDV).  Chronic distention of the heart 
results in detrimental cardiac remodeling that permanently dilates the heart; this results 
in weakening of the heart and decreased cardiac efficiency, as can be seen by the 
downward shift of the failed heart curve in Fig. 1.  This is due to the increase in energy 
needed to contract the heart due to the higher tensions from the over-stretching of the 
muscle fibers, known as the Laplace effect (Nicholson, 2007).  The process eventually 
results in inadequate cardiac function, leading to the death of the patient.   
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Current CHF therapies are insufficient in reducing cardiac dilatation and 
restoring natural heart function, creating a significant need for alternative treatment for 
CHF.  The development of an adjustable active cardiac assist device (AACSD) will 
enable a minimally invasive treatment option for patients with CHF that limits further 
heart dilatation by applying passive support, and restores natural cardiac motion by 
offering active assist.  The development of such an innovative Class III cardiac device is 
a lengthy process that requires thorough design research, bench top testing, prototyping, 
and animal studies before a design can be developed for clinical trials.   
The project scope is to perform design research towards the design and 
embodiment of the implantable components of the AACSD.  Implementation of the 
design process and embodied design proposed allows for the manufacture of a prototype 
for verification and validation of the design process and the embodied concept with 
continued proof-of-concept studies.  Once implemented, the design process can be 
applied to future device iterations for continued development of the AACSD.  
 




2.1 Current Device Therapies for CHF 
 Pharmacological therapies have been largely unsuccessful in overcoming the 
progression of CHF.   Recent studies have even indicated that increased pharmacological 
therapies may not be safe or effective (Mancini and Burkhoff, 2005).  As the change in 
stresses in the myocardium has become better understood, the development of device 
based therapies that target the changed stress environment has increased (Mancini and 
Burkhoff, 2005). Devices that focus on the application of mechanical forces are 
classified into blood contacting devices and heart contacting devices, which by nature do 
not contact the blood.  Blood contacting devices present the nontrivial problem of 
making the device hemo-compatible to limit complications from adverse reactions with 
the blood.  Mechanical devices that contact the blood include left ventricular assist 
devices and intra-aortic balloon pump counter-pulsation devices.   
Heart contacting devices are based on the discovery that wrapping the latissimus 
dorsi muscle (LDM) around the heart for passive support (known as static 
cardiomyoplasty), or for assistance through stimulation of the LDM with electrodes 
(known as dynamic cardiomyoplasty), resulted in opposition to dilatation and systolic 
augmentation, respectively (Vaynblat et al., 1997).  While the benefits of dynamic 
cardiomyoplasty have shown to be limited, the benefits of static cardiomyoplasty were 
encouraging due to the “girdling effect” the muscle offered (Power et al., 2003).  These 
benefits have driven the development for heart contacting devices that can be employed 
in a less invasive manner and composed of a prosthetic material with more suitable 
mechanical properties (Power et al., 2003).   
These devices can further be classified into cardiac support devices (CSDs) and 
direct cardiac compression devices (DCCDs).  CSDs focus on limiting further dilatation 
of the heart using passive mechanical support to offer resistance to the increased EDP.  
There are currently no comparable Food & Drug Administration (FDA) approved CSDs 
on the market; however, two notable CSDs are currently under development, and in 
 
          
4 
clinical trials that have produced favorable results. These studies indicate CSDs result in 
the reduction of mechanical wall stress, improved function, and reverse remodeling 
(Feindt et al., 2005). One such device is Acorn Cardiovascular‟s CorCap, seen in Fig. 2, 
which utilizes an inelastic polyester mesh that is wrapped around the heart through an 
invasive procedure.  Previous studies on the CorCap show its use provides a significant 
increase in left ventricular ejection fraction (Power et al., 2003), and reduced left 
ventricular volume and sphericity (Starling et al., 2007).  Despite its benefits, the 
CorCap possesses two significant concerns in its design:  the invasive procedure needed 
for its deployment around the heart and the inability of the inelastic mesh to adapt to the 
reduced heart size to provide adequate passive support. The second prominent CSD in 
development is Paracor Medical‟s HeartNet, seen in Fig. 3, which utilizes an elastic 
nitinol frame deployed around the heart in a minimally invasive procedure.  Such a 
design addresses the concerns of the CorCap (Klodell Jr. et al., 2008); however a new 
concern of the design is introduced:  the inability of the highly compliant nitinol mesh to 





Fig. 2. Depiction of CorCap around the heart.  
Figure from Power et al. (2003) 
 
Fig. 3. HeartNet around a model heart.   




DCCDs focus on active assist to promote more effective pumping of the heart 
through active mechanical forces.  One notable DCCD is the Anstadt Cup, which is 
composed of a silicone bladder, as seen in Fig. 4.  The bladder is pneumatically filled 
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and emptied, based on the cardiac cycle, to provide systolic and diastolic augmentation.  
Studies show the Anstadt cup is effective at improving pump performance (Anstadt et 
al., 2002); however, a principal concern of the device is that the design further promotes 









2.2 Use of Injection Ports and Transcutaneous Lines in Industry 
Subcutaneous injection ports have extensive use with patients requiring long 
term internal access for the delivery of drugs and withdrawal of blood.  While most are 
utilized to gain venous access, these ports can and are often used for other purposes 
requiring subcutaneous access; examples of devices that utilize injection ports to fill 
balloons include tissue expanders and adjustable gastric bands, such as the REALIZE 
Band and the LAP-BAND.   
For instances where continued internal access is needed, the healthcare industry 
utilizes transcutaneous lines; these include singular devices, such as percutaneous 
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catheters, and separate devices that utilize these lines, such as left-ventricular assist 
devices.  Examples of percutaneous catheters include central venous catheters (CVCs), 
peripherally inserted central catheters (PICCs), and midline catheters.  Catheters are 
made for short-term implantation (< 30 days) and long-term implantation (> 30 days).  
Risk of infection has been a primary concern for long-term percutaneous catheters, and 
many catheters possess additional features to reduce the risk of infection.    
Long-term catheters are made of highly biocompatible materials and may possess 
a cuff to promote tissue growth as a means for reducing the risk of infection; these 
catheters are known as tunneled catheters.  Non-tunneled catheters account for the 
largest percentage of catheter related infections (compared to non-transcutaneous 
catheters and tunneled catheters), while tunneled catheters have a significantly lower risk 
of infection compared to non-tunneled catheters (CDC&P, 2002).  While most catheters 
generally resemble open tubes, some catheters include an internal valve to prevent 
unwanted flow of media through the catheter for the purpose of reducing the risk of 
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3. RESEARCH AND DEVELOPMENT OF AASCD 
 
3.1 AACSD Architecture 
The AACSD system comprises of the following sub-systems:  implantable 
components, delivery components, and external components.  The implantable 
components consist of a novel collapsible cup, a subcutaneous injection port, and a 
percutaneous drive line.  The novel cup comprises of a frame scaffold, bladders for 
passive support and active assist, and components to provide support for the cup.  The 
delivery components consist of a deployer tube to clear access to the pericardial space 
and guide the collapsed cup for expansion around the apex of the heart.  The external 
components include a driver for the active system, pumps to fill and remove air from the 
active bladders, and equipment to monitor the performance of the device and the heart, 
such as electrocardiogram (ECG) wires and pressure catheters.   
The architecture of the implantable sub-system is shown in Fig. 5.  The cup is 
implanted beneath the pericardium and around the dilated heart.  The cup‟s bladders are 
controlled through two mechanisms, a passive control system and an active control 
system.  Adjustment of volume in the passive bladder, through saline injections into the 
port, allows the passive system to offer variable support to the heart.  Adjustment of the 
volume of the active bladder allows the active system to offer cyclical assist to the heart.  
The active bladder volume is adjusted by the pumps that are connected to the external 
system with a drive line to cycle air in and out of the bladder in sync with the cardiac 
cycle.  When activated, a custom LabVIEW based driver utilizes ECG gating to open 
and close solenoid valves to control the flow of air to the active bladder.  During the 
onset of systole, air is pumped into the active bladder.  After a prescribed period based 
on the ovine‟s ECG waveform, the air is cycled out of the active bladder using a trigger 
relay switch and solenoid valves.  
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Fig. 5. Device architecture for the implantable components of the AACSD.  Interaction with external 
components to provide the passive support and active assist are also shown. 
  
 
          
9 
3.2 Deployment and Operation of the AACSD 
Due to their compromised state, CHF patients are not suitable candidates for 
open-heart surgery; therefore, a minimally invasive implantation method is needed.  For 
implantation, a small incision is made in the chest.  The collapsed cup is placed in the 
terminal end of the deployer tube, and the deployer tube is inserted into the incision.  
The deployer tube consists of a curved tubular frame that clears the pericardial space to 
gain access to the heart apex. Upon exiting the deployer tube, the device frame expands 
the cup from its collapsed state and the cup is guided over the heart.  Once all 
components of the implantable system are in place, the ovine is sewn-up and device 
operation can begin.   
The primary function of the device is to provide passive support.  Operation of 
the passive system occurs for as long as the heart is in need of passive constraint to 
reduce EDV.  Expected duration of passive operation is on the order of weeks, but may 
vary by the severity the failed heart.  If active assist is required, the assist may be 
employed to supplement the passive support in the most severe cases, when the heart is 
in need of increased systolic performance to restore blood flow or re-perfuse the 
kidneys.  The active assist will be operated for short durations when needed.   
The therapy is intended to gradually wean the heart from the device by reducing 
heart size and restoring normal heart function.  Heart function is restored by promoting 
normal growth and remodeling in the heart that replaces entire muscle fibers every two 
weeks.  Once active assist is no longer needed, the drive line is removed, and the passive 
support remains as the sole function of the device.  Once passive support is no longer 
needed, the passive bladder is drained and the device remains implanted around the heart 
in a dormant state without rigidly constraining the heart or inhibiting cardiac 
performance.   
Unlike other CSDs that offer support through the elasticity of materials, the fluid 
filled bladders mimic the heart‟s natural environment – lungs that act as a damper to 
heart motion.  The fluid filled bladders encompass the heart in a similar dampening 
environment.  A vital function of the device is the ability to adjust the volume of the 
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bladders to conform the cup to the size of the heart, without offering rigid constraint. 
Feedback for determining appropriate adjustments for the bladder volumes is based on 
the ovine‟s central venous pressure (CVP).  This feedback system ensures damage to the 
heart from over inflation of the bladders does not occur.  The operating pressures of the 
device are expected to remain around 20 cm H2O. 
 
3.3 Prior AACSD Prototypes 
Previous prototyping by Dr. Criscione and his lab has focused predominantly on 
the generation of a variety of different configurations for bench top prototypes to test the 
kinematics, feasibility, and performance of the design.  Some configurations contained 
passive support and active assist, and others only passive support.  Fig. 6 shows a 
previous prototype with helically shaped passive bladders forming the internal cup.  
Configurations for improving deployment include the development of internal 
components to help flare the frame and configurations to better integrate the cup with the 











          
11 
Prototypes for previous animal studies have been configured for acute studies 
with invasive deployment, such as in Fig. 7.  Prototyping for interfacing with an 
implantable subcutaneous injection port and transcutaneous drive line has been limited. 
Instead, prototypes used in ovine proof-of-concept studies consisted of an assembly of 
tubes, wires, and catheters that connected to the external drive system, as shown in Fig. 
8; however, the bulky nature of the assembly of tubes is problematic for preventing 
infection.  Design of a concept for integration with an injection port and drive line must 
be addressed. 
While prototyping has developed a variety of designs for testing, embodiment for 
manufacture has been limited.  The prototypes have been constructed of non-medical 
grade materials, and concerns for manufacture of a prototype have not been a significant 
part of the design process.  To advance the development of the AACSD, these issues of 





Fig. 7. Previous prototype implanted in an invasive 
manner during an animal study.  
 
Fig. 8. View of percutaneous lines for inflating the 
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3.4 Results of Previous Animal Studies 
 Acute animal studies in ovines have been previously performed by Dr. Criscione 
and his research group to test the AACSD.  When the cup is in use, the increased rigidity 
of the cup, along with the removal of air in the chest cavity after implantation, draws the 
heart to the cup to prevent the heart from dislodging.  These proof-of-concept studies 
confirm the hypothesis that the passive support reduces the left ventricle size and active 
assist, if even for only 10 cardiac cycles, increases stroke work (Criscione, 2008).   In 
addition, when the device was not in use, the non-rigid cup did not interfere with cardiac 
function; cardiac parameters, such as cardiac output, CVP, wedge pressure, and aortic 
pressure, were not significantly different when the device was not in use than prior to the 
implantation (Criscione, 2008).  These results compare favorably to results of other 
CSDs and DCCDs; however the design offers advantages over other CSDs and DCCDs 
in that the adjustment of bladder volume allows for proper sizing of the device to 
adequately provide continued end-diastolic support as the heart reduces in size, and the 
design promotes natural growth and remodeling.  While further studies are needed to 
completely understand the potential of this therapy and optimize a device for treatment, 
the results of these studies support the continued development of an embodied design to 





          
13 
4. DESIGN PLAN FOR COMPLETING AIM I AND AIM II 
 
The design plan utilized for the embodiment of the AACSD, shown in Fig. 9, 
follows the use of design controls as recommended by the FDA in their guidance 
document “Design Control Guidance for Medical Device Manufacturers”.  Due to the 
novelty of the cup, this design plan model is needed for maintaining a quality system.  
Unlike the novel cup, the availability of FDA approved subcutaneous injection ports and 
transcutaneous lines allow for the use of an approved port and drive line to be interfaced 
with the cup, rather than the design of a custom port and drive line.  Utilizing 
components for the AACSD system that have prior FDA approval allows for the focus to 
remain on the novel cup design and its interfacing with the port and drive line.   
This plan utilizes a waterfall approach; the outputs of one phase are also the 
inputs for the subsequent phase.  Modeling the design plan of the research after this plan 
possesses two significant benefits.  The first is the design plan has been proven to set up 
a structure for verifying the design output maps to the design input, and validating the 
medical device maps to the user needs.  Secondly, the model allows for the design plan 
to be easily translated to future iterations of the design as different features are tested and 





Fig. 9. FDA Design Control process.  Figure from FDA (1997).  
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5. AIM I:  PROBLEM STATEMENT 
 
 The first specific aim is to develop a concept of a novel AACSD system for use 
towards the development of a manufactured prototype.  The design control process will 
be used in completing Aim I.  The initial phase is identifying and classifying the user 
needs.  Defining the user needs accurately is vital for ensuring the end product is 
something the user will desire.  The vagueness and subjectivity of user needs make them 
insufficient as criteria for developing a quality design; therefore a more explicit and 
objective criteria is needed.  To obtain these criteria, the classified user needs are used to 
develop the design inputs.  The purpose of the design input phase is to establish design 
requirements for the design process phase that will map to user needs. In addition, this 
phase is the basis for verification that the product meets the original design 
requirements.    Inputs into the design input phase are the user needs, and the outputs are 
the design requirements.  The design process phase consists of concept generation for 
each implantable component, and the selection of the best concept based on the design 
specification criteria generated.   
 The deliverables for Aim I include a design specification sheet for the AACSD 
cup, selection criteria for identifying suitable port and drive line candidates, and 
generating concepts for consideration.  Finally, the selection of the best cup concept, 
port, and driveline for integration into the AACSD implantable sub-system is performed 
based on the design input criteria.   
This design research supplements the prototyping research also being performed 
by Dr. Criscione and his lab.  The primary focus of the design research is to obtain a cup 
concept, port, and drive line by going through the design process; however verification 
of the design input criteria must be done through prototyping research and is not the 
focus of the design research.  
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6. USER NEEDS 
 
6.1 Interactions between the User and the AACSD  
To analyze the user needs based on product-user interaction, an activity diagram 
was created, seen in Fig. 10.  Activity diagrams identify customer needs by examining 
customer and product interaction, and characterize the needs into categorized specific 
needs (Otto and Wood, 2001).  The activity diagram begins with user‟s first interaction 
with the product, and ends with removal of the device from the ovine.  The activity 
diagram can be broken into five stages:  preparation, implantation, operation, dormancy, 
and explantation.  From the diagram it is seen that the surgeon is the direct user of the 
device and the patient is an indirect user. Target patients for this device are end-stage 
heart failure patients that are not eligible for a heart transplant list, so a therapy such as 
the one proposed is a last resort.  The importance of user-device interaction on user 
needs is evident; particularly so during the implantation stage and the operation stage.    
The surgeon‟s need for ease of user interaction during device implantation and operation 
is vital for meeting the needs of the patient, safety and proper performance.  Finally, 
product quality is important to ensure each of the functions in the operation stage can be 
performed as required.  The following categories for classifying user needs are 
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Fig. 10.  Activity diagram for the AACSD. 
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6.2 Interpreted User Needs 
To identify specific user needs based on the categories identified by the activity 
diagram, a customer needs assessment (CNA) was performed. A CNA is a researched 
based technique for determining user needs in the context of the product application, 
product environment, and customer characteristics.  The CNA, shown in Appendix A in 
Table 27, was completed through background research of previous methods of heart 
failure treatment, FDA regulations, and results of previous prototyping.  Combining the 
derived user needs from the CNA and the interfacing needs from the activity diagram 
produces a concise and thorough listing of interpreted user needs, shown in Table 1.  The 
user needs in the product performance category address what the device must do, and 
concerns the patient as the user.  The patient safety category outlines the importance of 
reducing device related risks and risks from implantation.  The ease of user interaction 
category addresses needs with the physician as the user, to allow the physician to 
successfully implant, access, and adjust the device.  Finally, product quality is necessary 





Categorized interpreted customer needs 
Category Interpreted Need 
Product Performance 
reduce heart size 
restore natural heart function / increase cardiac performance 
restore natural heart motion 
Patient Safety 
reduce risks of implantation 
not detrimental to heart when dormant 
reduce risks of infection 
Ease of User Interaction 
ease of monitoring device 
ease of operation 
ease of access to device 
Product Quality 
minimize risk of device failure 
design process follows FDA regulations 
device adequately stored 
adequate product lifetime 
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7. DESIGN INPUTS 
 
7.1 Functional Models 
Ensuring product functionality meets the user needs is an important part of the 
design control process; therefore the interpreted user needs were mapped to product 
functionality using functional modeling.  Functional models break down the product into 
sub-functions needed to transform product inputs into product outputs that meet the user 
needs.  The initial function model is a black box model, shown in Fig. 11.  The black 
box depicts “what” the device must do, rather than “how” it will do so, and consists of 
defining the main function of the device along with the inputs and outputs necessary to 
achieve this function.  The inputs and outputs are classified into three domains:  energy, 




Apply passive support and 
active assist to a failing heart
Fluid KE, Pneumatic 
KE, Heart KE
Fluid KE, Pneumatic KE,  
Device KE, Vibrational
Air, Needle, Saline
Active assist on/off, 
Fluid level to inject
 Successful/unsuccessful 








The main function of the product, apply passive support and active assist to a 
failing heart, is derived from the user needs.  The energy inputs reflect the driving force 
for filling the passive and active systems, and the hearts own kinetic energy to the 
device.  The energy outputs reflect the device imposes its own energy on the heart, and 
the driving force for emptying the passive and active bladders, along with vibration 
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energy that is generated in the process.  The material inputs and outputs reflect that all 
materials that are input into the device must be recoverable and leave the device as 
outputs.  The information inputs and outputs indicate user feedback entering and leaving 
the device.   
 For identifying the sub-functions, a function structure was created, shown in Fig. 
12. The function structure provides a systematic method of transferring user needs to 
product function, allowing verification and validation to later be performed.  Each of the 
inputs and outputs appearing in the black box are shown as inputs and outputs on the 
function structure, along with sub-functions the product must perform to obtain the 
outputs from the inputs.  The injection port is responsible for taking in the injection 
needle and saline, and transferring the saline to the passive bladder.  The driving force is 
the kinetic energy of the saline.  The drive line transfers air to the active bladders with 
the driving force of pneumatic kinetic energy.  Once imported, saline and air are 
distributed to their appropriate bladders and stored, where they act on the heart to 
perform their primary function of providing energy to the device to provide passive 
support and active assist to the failed heart.  Once no longer needed the fluids are 
distributed out of the bladders and transferred back to the injection port and drive line for 
removal from the system.  These sub-functions will be a focus for generating the design 
specifications for the device. 
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7.2 Cup Design Specifications 
The design requirements consist of functional requirements, interface 
requirements, and performance requirements.  Functional requirements dictate „what‟ the 
device should do, interface requirements dictate how the device must interface with its 
environment, and design constraints dictate „how‟ the device must perform (FDA, 1997).  
Once compiled, the design requirements will be the design specifications for the device.  
Due to the novelty of the cup, a specification sheet is required for concept generation.  
The design specification sheet for the cup is shown in Table 2.  Functional requirements 
are listed first, and interface requirements and performance requirements are listed 
together as constraints.  Each requirement indicates whether the specification is a 
demand (D) or a wish (W), and the method of verification.  Some verification methods 
are easily tested with the development of bench top models; other specifications require 
the manufacture of a prototype for testing. 
The functional requirements must be met to achieve adequate device 
performance, prevent the device from damaging the heart, and allow minimally invasive 
deployment.  The constraints list specifications concerning geometry, kinematics, 
materials, and production.  Geometric specifications are essential to ensure proper sizing 
of the device so it will take up minimal space in the pericardium, while still conforming 
to the patient‟s heart properly.  Kinematic specifications are needed to ensure proper 
operation and prevent obliteration of the heart cavity.  Material specifications ensure 
acceptable performance of the device in the presence of heavy cyclic loading from 
natural heart motion and the varying volumes of the passive and active bladders, and 
ensure the cup fibroses to the heart and can be sterilized.  Production specifications 
ensure the device will not damage the heart due to sharp corners or wires, and the ability 
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Table 2 
AACSD cup design specification sheet 
# D/W Requirement Verification Method 
Functional Requirements 
1 D 
Adjustable girdle providing passive support by 
allowing for nearly 50% reduction of cavity 
from deflated state to maximum inflated 
passive state 
Fill cavity of prototype with liquid at 
maximum and minimum volumes and 
measure to ensure Vmin/Vmax ≈ 0.5 
2 D 
Change in cardiac output < 3% when passive 
constraint is null 
Verify with cardiac output data from PV 
loops during animal studies 
3 D 
Device is collapsible for deployment in a 1 ¼" 
diameter cylindrical tube 
Measure maximum cross-section 
dimension of collapsed prototype and 
verify it is < 1 ¼"  
4 D 
Device flares  to 75% of natural diameter upon 
leaving deployer tube 
Measure diameter of prototype exiting 
deployer to ensure is > 75% of  max  
Constraints 
5 D 
Maximum deflated device volume is < 1% of 
EDV 
Verify with dimensional check on 
engineering drawings to calculate deflated 
cup volume to verify is less than 1% EDV 
6 W 
Cup conforms to patient's heart within a 5% 
volume basis when device is deflated 
Perform dimensional check of engineering 
drawings to calculate deflated cup 
volume, calculate heart volume from 
imaging, and compare to ensure the cup 
volume is within 5% of heart volume 
7 D 
When activated, residual cavity volume is   
> 50% of cavity volume when not inactive 
Fill prototype with fluid at passive and 
active states and measure cavity volume to 
ensure Vactive/Vinactive < 0.5 
8 D 
All materials used are legacy implant grade 
biomaterials 
Verify all materials have previous and 
acceptable use in FDA approved devices 
9 D 
Fluid impermeable pockets, tubing, and 
connections 
Verify with long term bench top testing of 
prototype at 20 cm H2O 
10 D 
Tissue contacting materials chosen fribrose to 
the heart 
Verify with extended prototype testing of 
device/tissue interactions  
11 W Device does not completely fibrose to heart 
Verify with extended prototype testing of 
device/tissue interactions that portions of 
cup are not fibrosing to heart 
12 D 
Mechanical failure must not occur for 200 
million heart cycles (≈ 5 yrs at 76 BPM) 
Perform accelerated cyclic stress/fatigue 
tests at 0→20 cm H2O with simulated 
heart loading 
13 W 
Mechanical failure must not occur for 1 billion 
heart cycles (≈ 25 yrs at 76 BPM) 
Perform accelerated cyclic stress/fatigue 
tests at 0→20 cm H2O with simulated 
heart loading 
14 D 
Mechanical failure must not occur after 110 
thousand cycles of active assist  
(≈ 24 hrs at 76 BPM) 
Perform accelerated cyclic stress tests 
from 0→20 cm H2O with active assist 
15 D 
Bladders have a bursting strength of > 20 cm 
H2O 
Verify with prototype test by filling 
bladders with saline to > 20 cm H2O 
16 D Consists of no sharp corners or wires Verify with engineering drawings 
17 D Production capacity ≈ 100 
Verify that materials and parts are 
available for small scale production 
18 D 
Materials can be sterilized and packed using 
current sterilization methods 
Verify with material literature 
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7.3 Selection Criteria for the Injection Port 
 Since the injection port is not designed, functional requirements, interface 
requirements, and performance requirements will not be needed for the design of the 
port, but rather for developing a list of acceptable candidate ports for integration into the 
device.  The selection criteria are shown in Table 3 in a similar format to the design 
specification sheet for the cup.  Unlike for the cup, the verification methods for the 
injection port will not be tests done for verifying the design, rather they are verification 
methods for verifying compatibility of the injection port.  Thus, the verification methods 
will not be experiments but rather they will be research driven, such as verifying the 
candidate port meets the requirement by analyzing manufacturer specifications for the 
candidate port. 
The functional requirements concern needs for the use of the port, and the 
constraints discuss the specifications regarding geometry, materials, and regulations.  
Geometric constraints for the injection port include site of implantation and use of a 
small sized port catheter, since rate of fluid flow is not a primary concern, to reduce risks 
of infection.  Force and energy specifications require the port to be capable of filling the 
passive bladders to a pressure of 20 cm H2O.  Material specifications concern the 
duration that the port may be implanted and biocompatibility, which is important as the 


















          
24 
Table 3 
Injection port selection criteria 
# D/W Requirement Verification Method 
Functional Requirements 
1 D 
Deliver fluid to and from external injection 
needle and passive bladder 
Verify with device literature and 
ensure compatibility in connections 
for interfacing 
2 D 
Self-sealing membrane from syringe punctures 
for at least 100 injections 
Verify with device literature and 
specifications that maximum number 
of injections is > 100 
3 W Maximum dimension of port < 1 ½" 
Verify in device literature and 
specifications that maximum cross-
section dimension of port is < 1  ½"  
Constraints 
4 D Injection Port can be placed securely in chest 
Verify device literature supports 
implantation in chest  
5 W 
Maximum OD of tubing connecting to passive 
bladder is 3.2 mm 
Verify with port specifications 
6 D 
Port capable of withstanding internal pressure 
of at least 20 cm H2O 
Verify with device literature and 
specifications 
7 D 
Port is designed for long-term implantation 
(> 30 days) 
Verify with device literature and 
specifications 
9 D Tube's distal end is open Verify with device literature 
10 D Current FDA approval Verify with FDA 
11 D Have ≈ 100 available for order 
Verify with manufacturer that port 
selected meets volume goal 
12 W Port has detachable attachment 





7.4 Selection Criteria for Drive Line 
Similar to the injection port, selection criteria are needed for developing a list of 
acceptable drive line candidates for integration in the device, shown in Table 4.  The 
functional requirements discuss specifications needed to fill and empty the active 
bladders and provide a seal to the environment capable of holding up to 20 cm H2O.  
The constraints concern kinematic, geometric, material, and regulatory concerns.  
Geometry constraints illustrate a design conflict.  The outer diameter of the drive line 
should be minimized to reduce the risks of infection; however, the inner diameter should 
be maximized to allow for more flow of air to be cycled in and out during active assist.  
Other geometric constraints include the line being long enough to extend out of the 
ovine at a distance to minimize movement at the exit site when the proximal end is being 
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adjusted by the physician, and the internal seal being located away from the exit site to 
minimize movement of the line at the exit site.  Force and energy specifications require 
the line to be capable of filling the passive bladders to a pressure of 20 cm H2O.  
Material constraints are important for minimizing the risk of infection and for holding up 




Table 4  
Drive line selection criteria 
# D/W Requirement Verification Method 
Functional Requirements 
1 D Deliver air to active assist bladders 
Prototype test verifying the active 
bladders can fill to 20 cm H2O 
2 D Remove air from active assist bladders 
Prototype test verifying the active 
bladders can be deflated  
3 D 
Provides seal to external environment when 
active assist is not in use, capable of holding 
up to 20 cm H2O 
Prototype test with the active 
bladders that seal holds up to 20 cm 
H2O 
Constraints 
4 D Maximum OD of 0.25 inches 
Verify with dimensional check on 
engineering drawings 
5 D 
Tube extends out of patient at least 6 inches 
from dermal boundary 
Verify with device literature and 
specifications 
6 D Tube is non-rigid Verify with device literature 
7 D Inner seal can hold at pressure of 20 cm H2O 
Verify with device literature and 
specifications 
8 D 
Tube capable of withstanding pressures up to 
20 cm H2O 
Verify with device literature and 
specifications 
9 D 
Tubing is designed for long-term 
implantation 
Verify with device literature and 
specifications 
10 D 
Seal is internal and > 2 inches away from the 
dermal boundary 
Verify with dimensional check on 
engineering drawings 
11 D Promotes tissue growth at dermal boundary Verify with device literature 
12 D 
Lifetime of 110 thousand active cycles  
(≈ 24 hrs at 76 BPM) 
Perform accelerated fatigue tests 
13 D Production capacity ≈ 100 
Verify with manufacturer that design 
selected meets volume goal 
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8. DESIGN PROCESS 
 
8.1 Concept Generation of the AACSD Cup 
 The first stage of the concept generation process for the AACSD cup involved 
individual and group brainstorming.  Between four and eight concepts variants each 
were generated for bladder shape and arrangement, interface between the active and 
passive bladders, frame design, and base components of the cup needed for support.  
These concepts were then evaluated based on the design criteria and their ability to 
provide the functions needed from the function structure.  All sub-group concepts and 
their evaluation are discussed in Appendix B. 
After evaluation, the leading concepts were included for consideration in an 
overall cup design.  For the passive and active bladders, the advantage of using a single 
global bladder include providing less restriction of fluid flow, especially in the active 
bladder, and easier method of assembly and manufacture.  For the bladder interface 
design, a 2-layer design is suggested for its ability to form the cup shape, while 
minimizing the passive bladder and active bladder adversely affecting the operation of 
each other.  However, an integrated concept possessed many advantages (along with the 
many disadvantages) over the 2-layer concept, so the integrated concept will be studied 
further.  The frame design suggested is an offset petal design due to its ability to better 
allow for rotation; however, the petal design will also be analyzed further due to its 
simplicity.  The cup base design suggests the benefits of a rotating base.  Such a design 
is naturally suited for pairing with the offset petal, however a regular base will also be 
considered due to its simplicity.   
Three overall cup design concepts were generated.  Table 5 shows the breakdown 
of each the overall cup concepts based on their individual sub-groups.  The three 
concepts chosen reflect an effort to piece together compatible concepts from different 
sub-groups, while maintaining a diverse range of cup concepts for consideration.  The 
first concept is a compilation of the sub-groups suggested from the concept generation.  
The second concept is a more conservative and simple concept that also utilizes two 
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layers of bladders, but minimizes the need for a more elaborate base.  The third concept 
is an integrated bladder concept with a single global bladder to perform both the passive 
and active roles and a regular base that will minimize the volume of the device.  





Overall cup concepts 
 
Overall Cup Concepts 
 
1 2 3 
Category Rotating Petal Integrated 
Passive Bladder Global Global Global 
Active Bladder Global Global Global 
Bladder Interface 2-Layer 2-Layer Integrated 
Frame Design Offset Petal Petal Petal 




Fig. 13.  Overall cup concepts generated for further consideration.  These concepts include (a) rotating 
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8.2 Port Candidates  
To gather a list of candidate ports to be considered for interfacing with the cup, 
thorough research was done on current injection ports on the market using the FDA‟s 
Registration and Listing Database.   Next, the list was trimmed of any ports that were not 
suitable for future consideration due to improper sizing, recent recalls, and the inclusion 
of unnecessary technology not needed for the basic functions described in the function 
structure.  Once completed, the process generated seven port candidates for 
consideration.  The port candidates and their manufacturers are shown in Table 6.  For 





Ports selected for consideration 






M.R.I. Hard-Base Port 
Titanium Dome Port 
Titanium Port 
M.R.I. Port 




8.3 Concept Generation of Drive Line  
The initial step of the concept generation process for the drive line looked closer 
at the design requirements for the active system.  From the function structure it is clear 
the driveline must perform the following functions:  provide external access to the active 
bladders for inflation and deflation, maintain mechanical integrity, and ward off 
infection that is common with percutaneous access. 
The results from the concept generation are two different design concepts.  The 
first uses a percutaneous tube with an internal seal, shown in Fig. 14 (a), and the second 
uses a valved catheter with the valve internal to the active bladder, shown in Fig. 14 (b).  
The difference between the two concepts is the first must be designed for use in the cup, 
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while the second concept uses a current FDA approved product, therefore only the 
interface must be designed.  In each case, a one tube design is preferred because it takes 
up less space and therefore reduces the risk of infection.  At the exit site, additional 
measures are needed to promote tissue growth to secure the line in the patient and to 
prevent infection.  To minimize tube movement at the exit site and prevent infection, the 























































Fig. 14.  Concepts generated for drive line.  Concepts include a percutaneous tube with internal seal (a), 
and a valved percutaneous catheter (b).  
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9. CONCEPT EVALUATION 
 
9.1 Concept Selection of AACSD Cup 
The next step of the design process for the AACSD cup is to evaluate the overall 
cup concepts from concept generation using concept selection.  To aid in concept 
selection, a common design technique, known as a Pugh chart, is employed.  Pugh charts 
are used in comparing multiple candidate methods to a list of criteria to determine the 
optimum candidate.  The criteria are taken directly from the specification sheet, to 
ensure the design outputs map to the design inputs. In a Pugh chart, candidates are rated 
against a datum candidate based on the design criteria.  If the candidate satisfies criteria 
more favorably than the datum, the candidate receives a “+1”.  For less favorable 
satisfaction of the criteria the candidate receives a “-1”, and for comparable satisfaction 
the candidate receives a “0”.  The highest score indicates the concept that best satisfies 
the design criteria. For each Pugh chart, the datum was selected based on the most 
simple solution or solution that had been previously prototyped by the lab.  While Pugh 
charts have extensive use in industry, assumptions of the method include that the criteria 
are weighted with equal importance, and that a limited ranking scale with three options 
to rank each candidate is sufficient; however, at this stage in the development process 
these assumptions are acceptable as the process is aiming to develop a design for further 
testing.  Once further prototype testing has developed a more final design towards the 
end of the development process, these considerations should be taken into account 
during the selection process. 
These overall cup concepts were evaluated using the Pugh chart in Table 7.  The 
design criteria are taken from the design specifications.  The top rated design of the cup 
was the rotating concept.  This design provides passive support and active assist with 
two separate global bladders.  With concerns of proper filling and emptying of bladders 
and maintaining a desired pressure, the global bladder assembly is able to accomplish 
each of these most easily.  The passive bladder is located on the inside of the cup and the 
active bladder is located on the outside of the cup.  An offset petal frame that resides 
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internal to the passive bladder, provides support for the cup shape, allows for the device 
to be collapsed and flare upon leaving the deployer tube, accommodates rotation of the 
heart, and prevents the active bladder from obliterating the cavity.  The cup takes up 
minimal volume that will allow it to fit in the pericardial space, and requires only a 




Pugh chart of overall cup concepts 
 
Candidate Concepts 
Criteria Rotating Petal Integrated 
Doesn't interfere with cardiac output when not in use 0 0 0 
Collapsibility 0 0 1 
Ability to flare around heart during deployment 0 0 0 
Ability to conform to heart 0 -1 -1 
Ability to obtain desired pressure 0 0 -1 
Adequate lifetime of design 0 0 -1 
Ease of deployment 0 -1 -1 
Ease of manufacture and assembly/costs 0 0 1 
Amount of material needed/cost 0 1 1 
Fit in pericardial space/overall volume 0 1 1 
Ability to handle rotation 0 -1 -1 
Ease of filling bladders 0 0 -1 
Ease of emptying bladders 0 0 -1 
Amount of tubing needed 0 0 1 
Avoid cavity obliteration 0 0 0 
Support for cup shape 0 0 0 
Reduces coupling of cup and tubing from rotation 0 -1 -1 




While the other designs had certain individual aspects that made them favorable, 
the petal concept is not as effective as handling rotation of the heart and the integrated 
concept had too many concerns on the difficulty of operating a device that utilizes a 
single bladder for passive support and active assist.  The overall design of the rotating 
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9.2 Concept Selection of Port 
For the port, selecting a candidate from the seven under consideration was done 
using a Pugh chart.  The criteria from the Pugh chart, shown in Table 8, come from the 
Port Selection Criteria.  To rate each candidate port, specifications from the 
manufacturer were used.  For a reference point, the Bard Access M.R.I. Port was used as 
the datum.  The Pugh chart indicates that the candidate ports were very close in their 
ability to meet the selection criteria.  The Bard Access M.R.I. Port and the 
Angiodynamics Infuse-A-Port both compared similarly based on their product 
specifications.  However, due to the unknowns of the Infuse-A-Port, and because the 
Bard Access M.R.I. Port was chosen as the datum, the recommendation is for selection 
of the Bard Access M.R.I. Port.  Research of the port reveals that there is no recent 
history with complications with the FDA regarding the manufacture or marketing of the 
port, such as product recalls, and the port is manufactured by a reputable company with a 


























































































































































Max injections at least 100 0 0 0 0 0 0 - 
Largest dimension < 1 ¼"  0 0 0 -1 0 -1 0 
Available for chest placement 0 0 0 0 0 0 0 
Catheter sizes available 0 0 0 0 0 0 0 
Legacy product 0 0 0 0 0 0 -1 
FDA approved/recent issues 0 0 0 0 0 0 0 
Catheter pre-attached 0 0 0 -1 -1 0 0 
Weight of Port 0 - - 0 0 -1 0 
Height of port 0 - - 0 0 0 0 
Septum diameter 0 - - 0 0 0 - 
Port body material 0 0 -1 0 -1 -1 0 
Catheter material 0 0 0 0 0 0 0 
MRI compatibility 0 0 0 0 0 0 0 
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9.3 Concept Selection of Drive Line 
 With concepts generated, the next step of the design process for the active system 
is concept selection.  The resulting Pugh chart is shown in Table 9.  The Pugh chart 
indicates that the design that best accomplishes the needed criteria is the valved catheter.  
The concept entails the insertion of the valved catheter into the active bladder, with the 
valved portion of the catheter contained in the active bladder and bladder sealed around 













Ease of filling active bladders 0 0 
Ease of emptying active bladders 0 0 
Provides seal to external environment when active  
assist is not in use, capable of holding up to 20 cm H2O 
0 0 
Infection concerns 0 0 
Fit in pericardial space 0 0 
Interfacing with Cup 0 -1 
Total Volume 0 0 
Ease of deployment 0 0 
Ease of Operation 0 1 
Amount of material needed/Cost 0 1 
Difficultly of manufacture and assembly 0 1 
Amount of tubing needed 0 0 
Kink-resistance in system 0 0 
Availability/Choices available 0 -1 
Prior use in other implants 0 1 
Σ 0 2 
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Here the previously mentioned design tradeoff becomes issue:  for patient safety 
and reducing infection risk, a smaller diameter catheter is desired; however, to aid in the 
filling and emptying of the active bladders a larger inner diameter is desired, which also 
requires a larger outer diameter.  With catheter advancements in reducing the risks of 
infection, and with no resolution available for increasing the efficiency in filling the 
bladders without increasing the size of the catheter, the design tradeoff can be resolved 
by using larger catheters that have features to prevent infection.   
Identifying valved catheter candidates was done in a similar manner as the 
injection ports.  Catheters are available with different numbers of lumens; typically 
catheters have one lumen, although some have as many as four lumens or more in a 
catheter.  However, the addition of internal walls needed to separate lumens within the 
catheter decreases the cross-sectional area available for airflow, thereby reducing the 
efficiency of filling and emptying the active bladder.  For this reason, only single lumen 
catheters were considered for the percutaneous drive line.  Three catheters are available 
for consideration, shown in Table 10.  While the technologies of these are similar, the 
method of accomplishing the valve seal is different in each case.  The Bard catheter 
utilizes a single valve at the distal end.  The Angiodynamics catheter uses two valves at 
the distal end to achieve this same operation.  The Navilyst catheter uses a valve located 
on the proximal end.  Table 34 in Appendix C lists the specifications for each valved 




Table 10  
Valved catheter selected for consideration 
Company Catheter Manufactured 
Angiodynamics CVC with LifeValve 
Bard Access Systems Groshong 




A Pugh chart was done to evaluate the valved catheters based on Drive Line 
Selection Criteria.  The Pugh chart of valved catheters, shown in Table 11, indicates that 
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the best valved catheter for use in the device is the Bard Groshong valved catheter.  The 
Groshong catheter is preferred because of its superior features to prevent infection to 
enable a larger catheter size, a valve at the distal end, a single valve to design around for 
interfacing, and a solid reputation.  The particular catheter chosen of the Groshong is the 
largest sized catheter available; all available catheter options are shown in Appendix B 
in Table 35.   
A Groshong catheter is shown in Fig. 16.  Each of the catheters possesses two 
cuffs to help prevent infection.  The first cuff is a VitaCuff Antimicrobial Cuff that is 
designed to secure the placement of the catheter and prevent migration of 
microorganisms.  In the figure, this is the more distal cuff.  The second is a cuff made of 
Dacron whose main responsibility is to promote tissue growth to ensure implantation of 
the catheter, but also acts to prevent migration of microorganisms to prevent catheter 































































Provides seal to external environment when active assist is 
not in use, capable of holding up to 20 cm H2O 
0 0 0 
Min ID of filling tube 0 1 -1 
Max OD of filling tube 0 -1 0 
Catheter capable of withstanding pressures up to 20 cm H2O 0 0 0 
Legacy implant biomaterials 0 0 0 
Infection concerns 0 -1 -1 
Fit in pericardial space 0 0 0 
Interfacing with cup 0 -1 1 
Ease of deployment 0 0 0 
Ease of operation 0 0 0 
Kink-resistance in system 0 0 0 
Location of valve 0 0 -1 
Length 0 0 0 
Σ 0 -2 -2 
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Fig. 16. Dual lumen Bard Access Groshong CVC.  The proposed design uses only a single lumen.  Figure 
from Bard Access Systems (Bard Groshong CVC, 2009).  
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10. AIM I FUTURE CONSIDERATIONS 
 
A limitation of the selected concepts is that they have not yet been verified.  The 
verification methods listed in the design specification sheet must be performed with a 
prototype.  Future studies and prototypes will likely change some of the design criteria 
and present a more optimal concept based on the design criteria.  However, the design 
process is made to accommodate these design changes; each of the design inputs (black 
box model, function structure, design specification sheet) are meant to be fluid 
documents that are updated throughout the design process once new information 
becomes available.  This allows for the process to be transferrable to future iterations of 
the device.   
 If desired, less reputable but cheaper ports are available as original equipment 
manufacturer (OEM) parts.  These OEM ports may be desirable for studies in the short 
term, however, for long term applications a more reputable port like the Bard Access 
M.R.I. Port will aid in allowing the focus future studies to remain on the novel 
components of the AACSD.  
 Previous studies have indicated that there is some concern of the ability to 
remove air from the active bladders.  To help promote fluid flow, a single global active 
bladder was proposed for the device.  To reduce the novel components of the device, a 
valved catheter was proposed for use as the percutaneous drive line over a designed 
percutaneous tube with an internal seal.  However, if the valve is not able to allow for 
enough air to pass through during the time frame, then the designed percutaneous tube 
concept may need to be revisited.  In this case, a larger diameter line with an internal 
seal must be designed.  This can be accomplished using a larger non-valved catheter, 
such as any CVC, or a simple silicone or polyurethane tube.  Finally, future iterations of 
the drive line may further integrate the external components by allowing for integration 
of monitoring devices within the drive line.  Devices that dictate the active assist 
parameters, such as ECG wires and pressure catheters for monitoring pressure within the 
bladder, may be included in the percutaneous line.   
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11. AIM II:  PROBLEM STATEMENT 
 
The second specific aim is to embody the selected concept of the AACSD 
system, consisting of an FDA approved subcutaneous injection port, an FDA approved 
percutaneous drive line, and the novel design of the AACSD cup developed in Aim 1.  
The results of the design process phase from Aim I were then used to develop the design 
outputs.  Design outputs are any work product or deliverable item of any design task in 
the overall design plan (FDA, 1997).   
The design embodiment consists of sizing of the device for fit around an ovine 
heart and the selection of properties for each of the components of the AACSD; this 
includes dimensions, quantity of components, materials, and methods of assembly.   
Once each of these is defined, evaluation of the embodied design was done using a 
failure modes and effects analysis (FMEA) to evaluate potential concerns for device 
failure, and provide recommendations for future iterations of prototypes. 
The design outputs will be the deliverables of the research, and include design 
embodiment methods, a parts list, engineering drawings of the selected concept, and the 
FMEA.  As mentioned previously, the design research supplements the prototyping 
research performed by Dr. Criscione and his lab.  As part of the design controls, the 
results of the design output phase are used to map to the design input phase for 
verification that the design outputs adequately fulfill the design inputs; this verification 
must be performed through additional prototyping research as part of maintaining a 
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12. SIZING AND ASSEMBLY OF THE AACSD 
 
12.1 Sizing of Cup 
With a design concept selected, embodiment of the concept begins with 
determining necessary sizing of the cup for the manufacture of a prototype.  Since focus 
of this research is for continued development of the AACSD cup for ovine proof-of-
concept studies, the sizing proposed herein will be for ovine hearts.   As the ovine heart 
dilates and begins to fail, the left ventricle becomes more spherical.  The spherical-like 
cross-section allows for modeling of the heart as a prolate ellipsoid, with defining 
dimensions of radius R (corresponding to the approximate radius of the heart at its 
maximum cross-section) and length L (corresponding to the length of the heart from the 
maximum cross-section to the heart apex).  It is important that the heart dimensions used 
for modeling the cup be measureable with non-invasive standard hospital imaging 
equipment to ensure the cup is the correct size.  To complement the heart model, the cup 
will be modeled as a semi-prolate ellipsoid, with the defining dimensions R and L 
mentioned previously.  A depiction of the shape of the cup overlaying an ovine heart is 










Fig. 17.  Depiction of the semi-prolate ellipsoid AACSD cup shape over an ovine heart.  Figure modified 




Dr. Criscione and his lab have developed castings of excised ovine hearts from 
previous studies for sizing of prototypes.   From these hearts, a standard size has been 
developed by the lab for the construction of bench top prototypes.  To coincide with the 
prototyping process, the same size is used for the embodiment of the cup of the selected 
design.  The embodied device has an upper perimeter of 12 inches (therefore R ≈ 1.91 
inches) and a length L of approximately 4 inches.  The sphericity of the design can be 
defined by dividing the transverse axis of the ellipsoid (R) by the longitudinal axis (L).  
A perfect sphere will have a value of 1, while a prolate ellipsoid that deviates further 
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 AACSD Design Specification #5 dictates that “maximum deflated device 
volume is <1% of EDV”.  EDV is the summation of EDV of the left ventricle and right 
ventricle.  While EDV varies for each heart, an approximation of 200 mL for EDV is 
acceptable.  Using this approximation, the maximum deflated device volume is 2 mL (or 
2,000 mm
3
).  The volume of a semi-prolate ellipsoid is shown in Equation (1).   
 
                                                                 𝑉 =
2
3
𝜋𝑅2𝐿                     (1) 
 
Using this calculation, an approximation for the maximum device thickness, t, can be 
obtained using the R and L previously defined above.  For calculating the volume, the 
volume of the wires is not taken into account, therefore this calculation is effective in 
calculating the maximum thickness of the bladders.  The thickness can be found by 
Equation 2, where Vcup is 2000 mm
3
, and Vouter and Vinner can be calculated by Equation 
3 and Equation 4, respectively.   
 
                                                       𝑉𝑐𝑢𝑝 = 𝑉𝑜𝑢𝑡𝑒𝑟 − 𝑉𝑖𝑛𝑛𝑒𝑟           (2) 
                                                      𝑉𝑜𝑢𝑡𝑒𝑟 =
2
3
𝜋 𝑅 + 𝑡 2(𝐿 + 𝑡)         (3) 
                                                           𝑉𝑖𝑛𝑛𝑒𝑟 =
2
3
𝜋𝑅2𝐿                     (4) 
 
The calculated maximum thickness for the bladders is approximately 0.087 mm; 
therefore a thin film must be used to create the bladders.  Due to the variability in heart 
size, a range of cup sizes will eventually be needed to sufficiently fit the device over the 
range of heart sizes.  Further research will need to be performed on the development of 
different sizes of the heart; however, the focus for the research is on the embodiment of a 
single design for verification testing.  Once verification testing has been performed the 
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12.2 Design Embodiment of Port 
The product details and specifications of the Bard Access M.R.I. Port are shown 
in Table 12.  This table shows the relevant port dimensions such as the diameter of the 
port base, port height, and septum diameter.  Also shown are other properties of the port 
such as weight and reservoir volume, catheter properties, and materials of the port and 
catheter.  The attachment method refers to if the port catheter is pre-attached or 
attachable by the physician.  Different catheter options are available on the selected Bard 
Access M.R.I. Port, including both silicone and polyurethane catheters.  The 
specifications for these catheters are shown in Appendix C in Table 35, and include the 
dimensions of the catheter and the type of end on the catheter.  Standard dimensioning 
for the outer diameter are given French size (Fr.) units; to convert to millimeters the 
French size is divided by 3.   
Due to the excellent mechanical properties of polyurethane, catheters composed 
of polyurethane possess thinner walls than silicone catheters.  However, since the 
pressures the catheter will be experiencing are relatively low during operation compared 
to the pressures the catheters are manufactured to withstand, the more expensive 
polyurethane catheters are not required for this application.  A valved catheter is also not 
needed for this application since the port, catheter, and passive bladder will form a 
closed system internal to the patient.  The selected catheter is the 9.6 Fr. radiopaque 
silicone catheter.  To aid in adjusting the device, an attachable catheter is recommended 
for integration with the port body.  This catheter meets the selection criteria and 
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Table 12 
Specifications of Bard Access M.R.I. Port (Bard Ports, 2009). 
Base diameter 31.5 mm 
Height 15.3 mm 
Septum diameter 12.5 mm 
Reservoir volume 0.6 mL 
Weight 8.9 g 
Base material Plastic   
Septum material Silicone   
Implant location Chest   
Catheter material Radiopaque silicone 
Lumen OD 9.6 Fr. 
Lumen ID 1.6 mm 
Catheter length 76 cm 
Catheter attachment Attachable 
MRI compatible Y   
Maximum number of 
injections 
2000 with 20 Gauge Needle 




12.3 Design Embodiment of Drive Line 
The product details and specifications of the Bard Access Groshong catheter are 
shown in Table 13.  This table shows the relevant catheter dimensions such as the outer 
diameter, inner diameter, length, and placement of the valve. The distal end of the 
catheter composes of a single valve that is designed for 3-way use, as shown in Fig. 18.   
The operating pressures of the valve are shown in Table 14.  At normal CVPs, 
the valve remains closed.  When negative pressure is applied inside the lumen, the valve 
opens inward to allow fluid to be withdrawn.  When positive pressure is applied inside 
the lumen the valve opens outward to allow fluid to be injected.  The maximum expected 
pressure in the active system is on the order of 20 cm H2O (or 14.7 mm Hg), well within 
the operating range of the valved catheter.  When the active bladders are filled, the 
pumps create a positive pressure in the catheter that will open the valve to the active 
bladder and allows the bladder to be filled.  When the pump terminates operation of 
filling the active bladder, the valve will close and create a seal that holds the pressure of 
the active bladder.  After the prescribed delay, the pump system shuttles air out of the 
active bladder by creating a negative pressure that opens the valve inward to allow air to 
be removed out of the active bladder.  When the pump system terminates vacuuming air, 
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the valve closes at the neutral pressure, and the active assist cycle is ready to be 







Chosen drive line specifications from manufacturer 
specifications (Bard Groshong Brochure, 2009). 
Catheter Material Silicone   
Lumen OD 2.7 mm 
Lumen ID 1.5 mm 
Length 65 cm 
Valve Type 1-valve   
Valve Location Distal   
FDA Approval Y   
Recent FDA Issues N   
 
 
Fig. 18.  Operation of the 3-way valve on the 
Groshong catheter.  Figure from Bard Access 








Valve operating pressures (Bard Groshong IFU, 2009) 
Valve Status Internal Pressure External Pressure 
Opens Inward Negative Pressure P > 80 mm Hg 
Opens Outward Positive Pressure P < -7 mm Hg 
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12.4 The Embodied Design of the Device  
 For embodiment, engineering drawings for each component were created, along 
with an assembly drawing showing the entire AACSD embodied design.  Each of the 
drawings indicates the dimensions and layout of each component.  The assembly and 
dimensioning were determined based on the sizing of the cup, results of previous 
prototyping, and the constraints of the other components of the system to allow for 
interfacing.   
 The passive bladder and its assembly are shown in Fig. 19.  The passive bladder 
begins as a single rectangular film.  Adhesive is used for folding the passive bladder 
onto itself along the bottom of the film to create a smaller dimension for the base, shown 
in grey in Fig. 19 (a).  The passive bladder is folded along each of the vertical fold lines 
in the adhesive area and allowed to set.  This results in a crenellated trapezoidal sheet as 
seen in Fig. 19 (b).  Crenellations are desired to allow the bladder to fill more effectively 
once the inner film fibroses to the heart; this can be seen in Fig. 20.  Next the bladder is 
folded in the hoop direction and bonded to create a circumferential film assembly, where 
the larger diameter at the top corresponds with the upper perimeter of the cup. Further 
dimensions of the passive bladder were determined by Dr. Criscione and his lab from 
prototyping; these passive bladder dimensions are shown in Appendix D in Fig. 35.  
Next the film is folded over along the horizontal fold line to create the bladder pocket 
where the saline, frame, and internal components reside.  Later in the assembly process 
the bladder pocket will be sealed around the base of the cup and the port catheter to seal 




















Fold and use adhesive 









Passive bladder formed.  




Fig. 19.  Passive bladder assembly.  The assembly begins as a film sheet (a).  The film is folded over on 
itself using adhesive to create a smaller base diameter (b), and then folded and bonded to itself to make a 
circumferential shape (c).  Finally the top half is folded down to form the bladder shape (d).  Sealing of the 

























The active bladder is a single film of the same material that is slightly longer in 
length.  The active bladder is assembled in a similar process as the passive bladder. The 
active bladder film is folded to fit around the passive bladder and attaches to the passive 
bladder along the top of the cup and around the base of the cup using a film welding 
process.  The shape of the film allows for the film to be attached to the passive bladder 
in this manner.  Fig. 21 shows the assembly of the film and its attachment external to the 
passive bladder.  Further dimensions of the active bladder were determined by Dr. 
Criscione and his lab from prototyping; these active bladder dimensions are shown in 
Appendix D in Fig. 36.  Later on in the assembly process the active bladder will be 
sealed around the base of the cup and the valved catheter to seal the bladder to hold the 
air for active assist.  The thickness of the deflated device is then equivalent to four times 
the thickness of the film.  To comply with the design a specification, a 20μm film 
thickness is suggested. 
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Folded over portion 
of active bladder
Fold and use adhesive 
















Fig. 21.  Active bladder assembly.  The active bladder begins as a film sheet (a).  The film is folded over 
on itself using adhesive to create a smaller base diameter (b), and then folded and bonded to itself to make 
a circumferential shape (c).  Finally the top half is folded down to form the bladder shape that fits around 
the already assembled passive bladder (d).  Sealing of the open sections of the bladder will take place later 
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One of the shaped wires and the entire frame of the wires configured into the 
frame shape are shown in Fig. 22.  The frame is composed of twelve identical wires 
spaced equally in the hoop direction to form the cup shape.  The wire is pre-bent to form 
and set the shape of the upper tip of each loop.  Each individual wire has one section that 
forms the outer frame and another section that forms the inner frame; the section of wire 
that makes up the inner frame is longer than the outer part of the loop to accommodate 








Fig. 22.  Wire and frame.  Shape of a wire for the frame assembly (a).  The shorter section of wire forms 
the outer frame, and the longer section forms the inner frame.  The frame is composed of twelve of these 




The inner wires of each loop of the frame are secured to the inner hub.  The inner 
hub is a ring that fits at the base of the cup, below the heart.  The hub consists of a 
plastic ring with twelve holes to allow attachment for each individual wire of the 
 
          
50 
scaffold.  Fig. 23 shows the inner hub.  The frame will first be attached to the inner hub 
by looping the wire through the hole and fixing the looped wire to the inner hub with 










In addition to the components described in the selected concept, previous 
prototyping indicates that to aid in flaring the wire for deployment, another internal 
component was beneficial.   This component is a sliding hub.  The sliding hub possesses 
channels that set the angle of flaring of the wire for deployment.  The hub resides 
between the inner hub and the upper tips of the frame and is free to slide along the inner 
wire. Once each of the twelve wires is attached to the inner hub, the other ends of the 
wires are passed through each of the channels in the sliding hub.   
The sliding hub design is a ring design that is conical in shape to help match the 
shape of the heart apex.  The sliding hub is shown in Fig. 24.  Further dimensions of the 
sliding hub are shown in Appendix D in Fig. 38.  The sliding hub is used for deploying 
the device around the heart.  When the device is in its collapsed state, the sliding hub is 
at the top of the frame assembly to hold the wires compactly.  Upon deployment, the 
sliding hub rests on the heart apex and the wires are pushed through the sliding hub 












Fig. 24.  Sliding hub.  The hub is designed to accommodate heart apex shape and flare frame during 
deployment.  Solid model shown in (a), and sketch depicting the channels that the inner frame wire passes 




Once the inner part of the wire frame has passed through the sliding hub, the 
outer part of the frame is attached to the outer hub in a similar manner as the inner hub.  
The outer hub is similar to the inner hub, except the outer hub has a larger diameter so 
that the outer hub may slide over the inner hub.  The two hubs are concentric and free to 
move relative to each other with minimal friction from rubbing against each other, and 
create the offset shape of the frame by having one end of each wire on the inner hub and 
the other on the outer hub.  The outer hub is showed in Fig. 25.  Further dimensions of 
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With the wires secured to the hubs, the rest of the frame assembly is assembled 
to prepare for the attachment of the passive bladder to encompass the scaffold.  A suture 
is run in a saw-tooth pattern around the hoop direction along each of the wire loops 
towards the upper tips to define the loop shape and secure the loops to each other.  Then 
a hoop suture is run around the upper perimeter of the cup to set the circumference of 
frame.  This suture can vary in length to help shape the frame to the size and shape of the 
ovine heart.  The sutures are passed over each tip in multiple loops before continuing on 
to the next frame loop.  Next adhesive strips are attached to each wire loop along the line 
of the saw-tooth suture.  The strips align in a uniform direction around the frame and act 
to secure the loops and provide a foundation for the attachment of the passive bladder.  
Finally, double-sided adhesive strips are attached to the single-sided adhesive allowing 





Fig. 26.  Frame assembly.  The assembly is composed of the twelve wires, a hoop suture to define the 
upper perimeter, a saw-tooth suture to connect each of the wires, and adhesive strips that fit over the saw-
tooth suture that provide a foundation for attachment of the passive bladder later on in assembly. 
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Fig. 27 shows the M.R.I. port.  Since the injection port was selected and not 
designed, complete engineering drawings were not needed of the port.  Dimensions of 
the port are shown in Appendix D in Fig. 40.  Shown are the major overall dimensions of 
the port (base diameter, height, septum diameter) and of the port catheter (French size, 
internal lumen diameter, and length) that are needed to display the port in an assembled 
drawing.  The port catheter is truncated in the drawing to allow for better visibility of the 
complete drawing.  The dimensions explicitly shown in the port drawing are exact, 
however the rest of the dimensions needed to create the port are approximate, as such 
detailed information was not available from the manufacturer, nor required for the 










 The Groshong valved catheter engineering drawing is shown in Fig. 28.  Like the 
injection port, complete engineering drawings were not needed for use in the design.  
Dimensions of the valved catheter are shown in Appendix D in Fig. 41.  Necessary 
dimensions such as catheter length, internal diameter, and outer diameter are 
dimensioned.  All other dimensions were approximated.  The drawing also includes the 
tissue cuff, anti-microbial cuff, and the valve.   
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 Fig. 28.  Bard Access Groshong valved catheter.  The distal end houses the 3-way valve, and the 




With the frame and hubs completely assembled, the bladders can now be 
attached to the frame assembly. Fig. 29 shows an exploded assembly of all the 
components prior to attaching the bladders.   The passive bladder film is ran external to 
the frame and then folded over the frame to encompass the frame.  Once in position, the 
film is pressed onto the adhesive strips to affix the film to the frame.  The looped hoop 
suture around each frame tip provides a buffer between the frame loop and the bladders 
along the upper rim of the cup.  The outer film is run down the cup frame and over the 
rest of the internal hub components.  An exploded view of the assembly with the passive 
bladder only is shown in Fig. 30(a).  The passive bladder is shown in a cross-section 
view for easier viewing.  As can be seen, the frame and hubs reside internal to the 
passive bladder.   Fig. 30(b) shows an exploded drawing of the complete bladder 
assembly in a cross sectional view with the active bladder assembled around the passive 
bladder.   
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Fig. 29.  Exploded view of the AACSD components prior to bladder assembly. 
  
 






Fig. 30.  Exploded cross-section with bladders.  The completed passive assembly is shown in (a), and the 
assembly with active and passive is shown in (b).  The active assembly shows the insertion of the valved 
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13.  MATERIAL SELECTION OF THE AACSD 
 
13.1 Passive and Active Bladder Materials 
Due to its innovation, the AACSD‟s path to market would be significantly more 
complicated using materials that are also innovative, as additional testing would be 
required to validate their safety.  Therefore, as stated in the design specifications, all 
materials must be legacy biomaterials.  Legacy materials have the benefit of being 
available in current devices, which serve to validate their safety and effectiveness.  
Materials are chosen based on the sub-functions the component must perform and on the 
design specifications.  Materials that contact the heart or pericardium must be implant 
grade materials and offer the required mechanical properties to accomplish each of the 
functions in the function structure, while materials housed internal to the bladders face 
less stringent biocompatibility requirements.   
The passive bladders will be contacting the heart; therefore a highly 
biocompatible material that is not abrasive is needed to prevent scarring of the heart.  
The material will be under a varying internal pressure from the saline; however, the 
pressures are relatively small.  In addition, the ability to form films of small thicknesses 
is needed to minimize the volume of the device to reduce its profile in the pericardium.   
There are many films that are used in a balloon concept similar to the application 
here.  Balloons are common in devices for balloon angioplasty, intra-aortic balloons, and 
tissue expanders.  Selection of materials for these balloons is made based on the 
mechanical properties needed and concerns of biocompatibility.  Some balloon catheters 
utilize a stiffer balloon material, such as polyester, that must be resistant to external 
forces in blood vessels.  Other balloons are designed to be more compliant, such as 
tissue expanders, which are typically made of silicone that is extremely flexible.  Other 
common materials available for medical films include polyurethanes and polyether block 
amides; both of these families are highly versatile in their properties and applications 
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based on their characterization and method of manufacture.  Common properties and 





Properties and uses of common material films for medical applications 
a: (Teoh, Tang, and Hastings, 1998), b: (Helmus and Hubbell, 1993), c: (Martins, 2004), d: (Kucklick, 2006), e: (Batich and Leamy, 2002), f: (Bhat, 2002), g: 




high elongation at break, high flexibility, 
low permanent deformation on static and 
dynamic loading, favorable friction and 
abrasion performance 
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, high versatility 
catheters, artificial heart 
bladders 
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, percutaneous leads, 




very stable, inert 
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implants, tissue expanders 
Polyester 
can be made into thin films, noncompliant, 









highly versatile, easy to bond with, ease of 
secondary operations 
d
, waterproof, low 
coefficient of friction, flexibility, can be 
made into thin films, and high versatility 
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The primary properties of the passive bladder require a flexible material with 
excellent mechanical properties that can be manufactured into thin films, while 
maintaining a water tight environment to contain the saline.  Due to the level of non-
rigidity needed for the passive bladder and the low-pressure application, a non-rigid 
elastomer is preferred for the design embodiment; therefore a more rigid film such as 
polyester is not preferred.  While the flexibility and biocompatibility of silicone is 
beneficial, the material possesses weak mechanical properties that do not make it a good 
choice due to the loading and unloading of the material from the heart and adjustment of 
bladder size, especially in thin films.  The polyurethane and polyether block amide 
families each offer excellent biocompatibility, strong mechanical properties, low 
coefficients of friction, and flexibility.  Polyurethane has extensive use in the medical 
balloon industry; however, its ability to be fashioned into thin films and maintain a 
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watertight environment is a concern.   Polyether block amides however can be processed 
into very thin films while still maintaining a water tight environment. 
With favorable biocompatibility and mechanical properties, and the ability to use 
very thin films to minimize volume of the device, a polyether block amide is suggested 
for use in the device.  One member of this family that has extensive use in the medical 
industry is Pebax.  Pebax is a thermoplastic elastomer used for coating for dental floss, 
medical textiles, and films (Pebax Medical, 2009).  Pebax is capable of being extruded 
using a cast or blown film process down to a thickness of 10μm (Pebax Processing, 
2009), which is well within the maximum specified thickness of the films.  The 
properties of Pebax are highly versatile; one particular film suitable for this purpose is 





Select properties of Pebax MV 3000 SA 01 
a: (Pebax MV 3000, 2009), b: (Pebax Medical, 2009) 
Tensile Stress at Break 
a
 35 MPa 
Tensile Strain at Break 
a
 500 % 
Flexural Modulus 
a
 45 MPa 
Hardness 
a
 35 Shore D 
Melting Point 
a
 158 °C 
Biocompatibility 
b
 USP class IV, free of additives and plasticizers 
Sterilization 
b




It is beneficial to use the same type of material for the active bladder as the 
passive bladder to minimize any unfavorable material interactions between the bladders.  
The material should be elastic to preserve the integrity of the bladder over the range of 
operating stresses and should have sufficient fatigue strength to handle the cyclic 
inflation and deflation.  Like the passive bladder, biocompatibility, good mechanical 
properties, and the ability to be made into thin films are primary concerns; therefore 
Pebax is also suggested as the material for the active bladder.  The active bladder must 
be attached to the passive bladder along the upper rim and the base; this can be done 
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using an adhesive to bond the bladders together or through thin film welding techniques, 
such as high frequency welding (Pebax Welding, 2009). 
 
13.2 Frame Materials 
The frame consists of a metal wire scaffold.  Since the entire frame is contained 
within the passive bladder, biocompatibility of the material is not a primary concern; the 
primary concern of the frame is mechanical properties of the material needed to achieve 
its main functions:  flaring the cup from its collapsed state, providing structure for the 
cup, and adapting the cup to the changing shape of the heart.  Unlike the bladders, which 
must be custom manufactured, metal wires for assembling the frame are available for 
purchase as standard parts in industry.   
Metal wires for medical applications are typically either stainless steel 316L or 
nitinol.  Of the two materials, nitinol possesses many unique mechanical characteristics 
that make it a suitable choice for the frame.  Nitinol is a shape memory alloy that allows 
for the variability of many of its mechanical properties based on the material 
composition and the manufacturing process.  The principal concern of the frame is 
ensuring it flares the cup for deployment from its collapsed state.  Unlike stainless steel 
316L, which may be readily deformed, nitinol can be made into a super elastic alloy that 
possesses excellent resistance to deformation and can spring-back to its original shape.   
Nitinol can be made into different phases by adjusting the transformation 
temperature of the alloy.  For super elasticity, deformation slightly above its 
transformation temperature results in stress-induced changes in the material 
microstructure.  Once the stress is removed, the material microstructure returns to its 
original microstructure, resulting in the metal returning to its original shape.  This 
process gives the nitinol excellent kink resistance, strain recovery, and flexibility.  For 
this application, the nitinol used should possess a transformation temperature below 
room temperature to ensure that it possesses these super elastic properties for operation 
at normal body temperature.  The super elastic nitinol prevents plastic deformation from 
collapsing the device for implantation and springs the device open for deployment 
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around the heart.  Given the elasticity needed for deploying the device and for adapting 
to the heart‟s motion, nitinol is selected for use in the frame.  Table 17 shows the 
composition of super elastic nitinol, and Table 18 shows select mechanical properties of 





Composition of super elastic nitinol  
(MatWeb, 2009) 
Carbon ≤ 0.05 % 
Iron ≤ 0.05 % 
Nickel 55.3-56.3 % 
Oxygen ≤ 0.05 % 
Titanium 43.55-44.7 % 
 
Table 18 
Select mechanical properties of super elastic nitinol 
(MatWeb, 2009) 
Tensile Strength, Ultimate 155 ksi 
Tensile Strength, Yield 118 ksi 
Elongation at Break 8 % 
Lower super elastic plateau stress 20 ksi 





13.3 Internal Components Materials 
The internal components consist of the following:  outer hub, inner hub, and 
sliding hub.  Due to their location within the passive bladder biocompatibility is not a 
primary concern, and since the components will not be under high stress, mechanical 
properties are also not a significant concern.  It is beneficial that these components be 
composed of similar materials to avoid unfavorable interactions between dissimilar 
materials.  The geometries of these components are simple and the parts themselves are 
small in size.  Advanced manufacturing processes, such as injection molding have heavy 
up-front costs that makes the process suitable for large scale production, but not for 
small scale production.  Since the number of parts needed to be produced is on the order 
of 100, such advanced manufacturing processes are not feasible for the manufacture of 
the internal components for further prototyping and animal studies. 
 A feasible process for obtaining parts of this nature for small scale production is 
rapid-prototyping (RP).  RP is a process used by many small companies and researchers 
to develop parts of precise geometries with low cost and quick turnaround.  The 
development of expensive molds is not necessary.  Instead, many RP techniques can 
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manufacture components straight from 3-D drawings.  One popular RP process that can 
be used for the development of the inner hub, outer hub, and sliding hub is 
stereolithograpy (SLA).  SLA uses a layer building process to construct the part.  A laser 
cures an ultraviolet light sensitive polymer of the desired cross-section one layer at a 
time.  After the layers have finished building on top of each other, the part is post-
processed to set the shape and remove any unwanted resin.  SLA is capable of producing 
rigid polymers with high tolerances and good surface finishes.  While materials used for 
SLA do not possess the same mechanical properties as engineering plastics, the hubs 
will not be undergoing large stresses and therefore are suitable for SLA design.   
 
13.4 Assembly Components Materials 
 For assembly, original equipment manufacturer (OEM) adhesives and sutures 
can be utilized.  Nylon sutures can be used in the assembly; they are prevalent in the 
medical field and provide excellent tensile strength, ability to knot, resistance from 
fraying, and resistance to elongation.  Adhesives are needed for use internal to the 
passive bladder to attach the wires to the hubs, to assemble the passive and active 
bladders, and to attach the passive bladder to the frame.  Since these adhesives will be 
internal to the passive bladder, medical grade adhesives are not needed.  For attaching 
the nitinol wires to hubs, an adhesive such as cyanoacrylate can be used to bond the 
nitinol to the hubs, or suture can be used to mechanically join the wire and hubs.  For the 
attachment of the passive bladder to the frame, commercial quality adhesive melt strips 
can be used.  The adhesive can be melted in its desired location and upon drying the 
adhesive effectively bonds the bladder together.  Prototyping has validated its ability to 
create a sufficiently strong bond and hold in the presence of saline.  This is preferred 
over two part adhesives or light curing adhesives due to its ease of construction.  For 
creating the seal of the passive bladder to the port catheter and active bladder to the 
valved catheter, a medical grade adhesive is needed since it is not internal in the device.  
Typically ultraviolet light cure adhesives are used in similar catheter assembly processes 
(Kucklick, 2006), and these adhesives can be to assemble the bladders and catheters.  
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14. DESIGN OUTPUTS AND DESIGN EVALUATION 
 
14.1 Parts List 
With the design and materials for embodying the design selected, a parts list can 
be generated for the design output stage.  The parts list details each component of the 
design, and includes the number of parts needed, part material, dimensions, a description 
of the part, and functions of the part.  The Parts List for the AACSD is shown in Table 
19.  The parts list is broken into separate sections.  The first contains the passive and 
active bladders.  These may be manufactured through extrusion processes such as blown 
film extrusion.  This process is commonly used for creating thin plastic films for a wide 
variety of applications, including medical device packaging.  The nitinol wire, sutures, 
and adhesives are available as OEM products.  The internal hubs can be manufactured 
using RP.  Finally, the port, port catheter, and valve catheter are available from Bard 
Access Systems.  For complete dimensions refer to the engineering drawings in 
Appendix D. 
 
14.2 Failure Modes and Effects Analysis 
The final production specification generated is an FMEA.  This is an evaluation 
tool for the embodied design to provide a look at the weaknesses of the concept design 
described herein and is useful for future studies to identify possible failure modes of the 
design to provide recommendations for future prototype iterations.  Failure modes of the 
port and catheters were included; however failure in these components is unlikely due to 
















Part# Sub-component Qty. Material Dimensions  Description Function 
1 Passive Bladder 1 
Pebax MV 3000 
SA 01 
12" length, 14" height, 
20 μm thickness 
Thin film which folds over 
frame to form bladder 
Form passive bladder, provide 
barrier between device and 
heart 
2 Active Bladder 1 
Pebax MV 3000 
SA 01 
12.75" length,  14" height,  
20 μm thickness 
Thin film attaches to top 
and base of cup around 
passive bladder 
Form active bladder, provide 
barrier between device and 
pericardium 




8.25" wire lengths - 3.75" outer 
and 4.5" inner lengths 
Wire proximal end at inner 
hub and distal end at outer 
hub 
Flare cup around heart during 
deployment, provide cup 
structure, promote proper 
kinematics of device 










Single-sided plastic melt 
adhesive strips fashioned to 
upper portion of outer 
nitinol wire 
Mate individual wires to allow 
for collapsibility of device but 
limit expansion in hoop 
direction, provide attachment 










Double-sided plastic melt 
adhesive strips 
Mate frame and passive 
bladder by covering single-
sided frame adhesive strips to 
provide attachment area for 





≈ 16" length, vary based on 
assembly 
Medical suture 
Provide firm connection 
between individual wires in 
frame with saw-tooth pattern 
along frame adhesive strips 
8 Hoop Suture 1 Nylon 12" length Medical suture 
Provide barrier between frame 
and passive bladder at tips, set 
frame upper diameter  







0.75" width by ≈ 7" length 
wedges 
Plastic melt adhesive cut 
into wedges 
Reduce size of bottom 
circumference of bladder, help 








Table 19 Continued 







1.625" width by ≈ 7" length 
wedges 
Plastic melt adhesive cut 
into wedges 
Reduce size of bottom 
circumference of bladder, 
help create crenellation of 
bladder 





Bottom OD: 0.5", Bottom ID: 
0.25" 
Top OD: 1", Top ID: 0.75" 
Height: 0.375" 
Channel Radius  
of Curvature: 0.25" 
Channel Diameter 0.031" 
Conically shaped shell that 
contains a channel for each 
inner nitinol wire 
Aid in deployment by 
matching with apex and 
promoting flare of frame 





OD:  0.5", ID: 0.438" 
Height: 0.188" 
Hole Diameter: 0.063" 
Cylindrically shaped ring 
that contains 12 holes for 
the nitinol wires and suture 
Base connection for inner 
nitinol inner 





OD:  0.625", ID:  0.563" 
Height:  0.188" 
Hole Diameter: 0.063" 
Cylindrically shaped ring 
that contains 12 holes for 
the nitinol wires and suture 
Base connection for outer 
nitinol wire 
15 Port 1 
Base:  Plastic 
Septum:  
Silicone 
Base Diameter:  31.5mm 
Septum Diameter:  12.5mm 
Height:  15.3mm 
FDA approved, M.R.I. 
compatible, up to 1000 
injections with 19 Gauge 
Needle 
Delivering and removing 
saline subcutaneously 
16 Port Catheter 1 Silicone 
OD:  3.2 mm (9.6 Fr.), ID:  
1.6mm  
Length:  76cm 
FDA approved, open-ended 
Transfer saline to and from 





OD:  2.7 mm (8.0 Fr.), ID:  
1.5mm  
Length:  50cm 
FDA approved, 3-way 
valve on distal end 
Transfer air to and from 
external pump system and 




          
The FMEA lists the functions and potential failure modes of each part.   For each 
failure mode, three categories are examined.  The first is the potential effects of the 
failure.  The severity of these effects is rated and given a number based on the scale 
shown in Table 20. The second category is potential causes for the failure.  The 
likelihood of occurrence of the causes generating the failure is rated and given a number 
based on the scale shown in Table 21.  The third category is current controls in place to 
prevent or detect the failure from occurring beforehand.  The likelihood of detection is 





Scale for potential severity (S) (Otto and Wood, 2001) 
Scale for Potential Severity (S) 
1 No effect 
2 Very minor (only noticed by discriminating customer) 
3 
Minor (affects very little of the system; noticed by average 
customer) 
4/5/6 Moderate (most customers are annoyed) 
7/8 
High (causes a loss of primary function; customers are 
dissatisfied) 
9/10 
Very high and hazardous (product becomes inoperative; 
customers are angered; the failure may result unsafe 






Scale for likelihood of occurrence (O) (Otto and Wood, 2001) 
Scale for Likelihood of Occurrence (O) 
1 No effect 
2/3 Low (relatively few failures) 
4/5/6 Moderate (occasional failures) 
7/8 High (repeated failures) 







          
Table 22 
Scale of likelihood of detection beforehand (D) (Otto and Wood, 2001) 
Scale of Likelihood of Detecting Beforehand (D) 
1 Almost Certain 
2 High 
3 Moderate 
4/5/6 Moderate - most customers are annoyed 
7/8 Low 




Next the Risk Priority Number (RPN) is calculated by Equation 5, 
 
                                                RPN = (S) x (O) x (D)                               (5) 
 
The range of the RPN is 1-1000, with the higher the numbers indicating increased 
concern for failure.  It should be noted that the scale is not linear.  Ratings above 100 are 
defined as being likely to occur and should be revisited to reduce the risk of failure (Otto 
and Wood, 2001).  Ratings below 30 are typical for products and are reasonable (Otto 
and Wood, 2001).  Based on the RPN, recommended actions are suggested for revisiting 








        
 
Table 23 




Potential Effect(s) of 
Failure 
S 
Potential Cause(s) of 
Failure 
O 
Current Controls - 
















4 over inflation, over use 2 
use material with strong 
mechanical properties 






cyclic loads from 
volume changes and 
from heart 
3 
use material with strong 
mechanical properties 









use material with strong 
mechanical properties 
5 100 animal study to test 
 
Unstable cavity obliteration 10 over inflation 3 
in short term care taken not 
to over inflate, in long term 
bladder fibroses to heart 
4 120 
careful monitoring 
during initial use; 
animal study to test 
 
Tear put hole in bladder 8 inadequate deployment 2 
use material with strong 
mechanical properties, 











catheter, leaking and 





use of standard methods of 
heat bonding 
2 48 animal study to test 
Active 
Bladder 
Store Air, Import 








4 over inflation, over use 3 
use material with strong 
mechanical properties 






cyclic loads from 
volume changes and 
from heart 
6 
use material with strong 
mechanical properties 









use material with strong 
mechanical properties 










use of a stiffer material to 
promote direction of 
inflation inward 
3 90 animal study to test 
 
Tear put hole in bladder 8 inadequate deployment 3 
use material with strong 
mechanical properties, 











catheter, leaking and 





use of standard methods of 
heat bonding 
2 48 animal study to test 
 
 




        
 




Potential Effect(s) of 
Failure 
S 
Potential Cause(s) of 
Failure 
O 
Current Controls - 








Shape device to 
heart, provide cup 
structure / Secure 









use of super elastic nitinol, 
allow for degree of freedom 
at connections 
3 9 






4 improper assembly 2 
allow for degrees of 
freedom at connections 
4 32 
bench top testing of 
operation 
 
Fatigue weakened frame 4 
varying loads from 
heart and bladders 
3 
use material with strong 
mechanical properties 
3 36 






3 improper assembly 2 
use of sutures and adhesives 
to help define frame shape 
1 6 
prototype testing of 
assembly 
 
Creep weakened frame 4 
prolonged stress from 
bending 
3 
use material with strong 
mechanical properties 
4 48 




wears hole through 
bladder 
8 
abrasive ends or 
surface 
2 
bladder will be filled to act 
as a buffer, smooth material 
is used, knots lift passive 
bladder off frame 
2 32 





detachment of wire 
from hubs, loose 
wire could damage 
bladder 
8 
inadequate amount of 
adhesive used, 
insufficient contact 
area of adhesive 
3 
use of legacy adhesive 
compatible with frame and 














use of material resistant to 
saline 
2 18 





9 improper deployment 2 
use of a mechanically 
strong polymer 
2 36 






3 improper assembly 2 use a symmetrical design 1 6 











use of a mechanically 
strong polymer 
2 16 





wears hole through 
bladder 
8 abrasive surface 4 
selection of a manufacturing 
process capable of smooth 
surfaces 
2 64 
bench top testing of 
operation 
  Wear 
weakening of hub, 
abrasive particles in 
bladder 
4 
rubbing with other 
hubs 
3 
sizing specifications to 
minimize rubbing 
3 36 










        
 




Potential Effect(s) of 
Failure 
S 
Potential Cause(s) of 
Failure 
O 
Current Controls - 












use of material resistant to 
saline 
2 18 





9 improper deployment 2 
use of a mechanically 
strong polymer 
2 36 






3 improper assembly 2 use a symmetrical design 1 6 











use of a mechanically 
strong polymer 
2 16 





wears hole through 
bladder 
8 abrasive surface 2 
selection of a manufacturing 
process capable of smooth 
surfaces 
3 48 
bench top testing of 
operation 
  Wear 
weakening of hub, 
abrasive particles in 
bladder 
4 
rubbing with other 
hubs 
4 
sizing specifications to 
minimize rubbing 
3 48 




Secure outer  
nitinol scaffold 




use of material resistant to 
saline 
2 18 





9 improper deployment 2 
use of a mechanically 
strong polymer 
2 36 






3 improper assembly 2 use a symmetrical design 1 6 











use of a mechanically 
strong polymer 
2 16 





wears hole through 
bladder 
8 abrasive surface 3 
selection of a manufacturing 
process capable of smooth 
surfaces 
3 72 
bench top testing of 
operation 
  Wear 
weakening of hub, 
abrasive particles in 
bladder 
4 
rubbing with other 
hubs 
4 
sizing specifications to 
minimize rubbing 
3 48 







Attach frame to 
hubs / Define 
nitinol scaffold 
shape, buffer for 
bladder / Secure 
frame 
Fatigue 
weakening of suture, 
break in suture 
2 overstressed 3 
use of a medical grade 
suture 




4 improper assembly 2 
use of a medical grade 
suture 
3 24 animal study to test 




use of a medical grade 
suture 








        
 




Potential Effect(s) of 
Failure 
S 
Potential Cause(s) of 
Failure 
O 
Current Controls - 









to frame / Form 







inadequate amount of 
adhesive used, 
insufficient contact 
area of adhesive, 
3 
use of legacy adhesive 
compatible with frame 
and bladder materials 
2 48 









use of legacy adhesive 
compatible with frame 
and bladder materials 
3 27 






4 improper assembly 4 
use a symmetrical 
design 
3 48 
prototype testing of 
assembly 
  Wear 






use of legacy adhesive 
compatible with frame 
and bladder materials 
3 18 
bench top testing of 
operation 








7 over injection, overfill 1 
selection of port made for 
operation within pressure 
range 
2 14 
bench top testing of 
operation 
Cracking 






selection of port made for 
long term use 
2 14 
bench top testing of 
operation 
 




selection of port made for 
long term use and with 
good reputation 
1 7 
bench top testing of 
operation 
 




selection of port for long 
term use 
2 10 animal study to test 
 
Misalignment 







selection of port made for 
chest cavity and with 
established reputation 
2 12 
prototype testing of 
assembly 
  Loose fittings 







selection of port with 
secure attachment 




passive bladder Fatigue leak of fluid 6 overstress 1 
selection of catheter made 
for operation within 
pressure range 
2 12 
bench top testing of 
operation 
Cracking 






selection of catheter with 
established reputation 
2 14 
bench top testing of 
operation 
  Misalignment kink in line 3 improper implantation 2 
selection of catheter with 
established reputation 
2 12 









        
 




Potential Effect(s) of 
Failure 
S 
Potential Cause(s) of 
Failure 
O 
Current Controls - 










valve no longer 
functions in normal 
operating range 
5 
over stress, flow rate 
too high 
3 
selection of catheter and 
valve made for operation 
within pressure range 
3 45 
bench top testing of 
operation 
Misalignment 
kink in line, valve 
doesn't open to 
bladder 
8 
improper assembly or 
implantation 
5 
selection of catheter with 
established reputation 
3 120 





movement of line 





have seal within bladder, 
use of tunneled catheter 
3 84 animal study to test 
 
Cracking 






selection of catheter with 
established reputation and 
made for long term use 
2 14 




can't empty or fill 






selection of largest ID 
valved catheter in line 
2 112 
bench top testing of 
filling bladder 
 
Wear infection 6 biological environment 2 
selection of catheter with 
established reputation and 
made for long term use 
2 24 animal study to test 
  Fatigue 
leak of fluid, valve 
no longer works in 
normal operating 
range 
7 too many cycles 5 
selection of long term 
catheter and valve made for 
operation within pressure 
range 
3 105 




          
For the passive bladder, the largest concerns are the threat of cavity obliteration 
and creep.  The frame protects the active bladder from obliterating the cavity, but care 
must be taken while filling the passive bladder to prevent cavity obliteration; however, 
the relatively static nature of the passive bladder limits its ability to obliterate the cavity.  
Long term studies to test the effects of creep on the passive bladders are needed; 
however Pebax possesses good mechanical properties, so creep is not expected to be a 
significant concern.  Bonding failure is also a concern since it has not been previously 
looked at during prototyping; however, Pebax bonds easily and many medical grade 
adhesives are used in high-pressure applications.  For the active bladder, the largest 
concerns for failure are fatigue, creep, and pericardial sac obliteration.  Further fatigue 
testing is needed; however, the good mechanical properties of Pebax along with the 
limited duration needed for active assist and the absence of high pressures give promise 
to the design proposed.   
 For the frame the primary concerns are bonding failure; however cyanoacrylates 
have prior use bonding to nitinol and sutures may also be used to secure the wires.  The 
smooth surface of nitinol is beneficial to reduce the risks of scratching.  In addition, the 
passive bladder will be inflated for most of its use, causing the bladder to inflate away 
from the frame and reduce the risk of scratching. The primary concern of the hubs is 
abrasive scratching to create a hole in the bladder. This risk is reduced by creating hubs 
of a smooth surface finish and inflating the passive bladder so that the material is 
inflated away from the hubs.  The sutures did not exhibit any large concerns as their 
failure is not likely to be very severe.  The adhesive failures are similar to the concerns 
of the bonding failure in the bladders.  The concern for failure of the port or port catheter 
is minimal due to their FDA approval for higher pressure applications.  The innovative 
use of the valved catheter to shuttle air and out of the active bladder dictates that 
additional testing is needed to ensure the seal will not yield over the course of its 
operation, and that the catheter is sufficient to remove and add air to the active bladder in 
the limited time frame.  Additional concerns for ensuring the valve is not blocked or 
misaligned and the effects of vibrations in the line must also be tested. 
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15. AIM II FUTURE CONSIDERATIONS 
 
15.1 Verification of the Embodied Design 
The design plan for the AACSD proposed herein provides a model for the design 
of future prototypes and follows the design control process.  For future iterations, steps 
of this design plan should be reviewed to assure that all steps are applicable, and 
revisions made where needed.  For example, it may come to light that the design 
specifications may need revision upon further testing.  This would involve appropriately 
adjusting the design specification and then making adjustments to the design plan as 
necessary.  The plan proposed herein also allows for a framework of verifying that the 
design output meets the design input, before continuing onto the medical device phase of 
the design process.   
  
15.2 Development of Multiple Sizes of the Device 
The development of a sizing algorithm for the manufacture of multiple sizes of 
the device will be needed to have an appropriately sized device due to the variability of 
the heart shapes and sizes.  Due to the wide range of sizes, continued studies must be 
performed to develop a product line for the device.  Overall heart geometry is attainable 
for each ovine prior to implantation in a non-invasive manner using imaging, such as 
echocardiography.  Other CSDs also have multiple sizes to account for this difference; 
for example the HeartNet is available in 16 different sizes for human heart use (Klodell 
et al, 2008), while the CorCap is available in the 6 different sizes for human heart use 
shown in Table 24 (Acorn, 2009).  The inability of current CSDs to adapt to the shape of 
the heart is the reason why so many of these sizes are needed.  Conversely, the Anstadt 
Cup DCCD uses three different models, based on the ventricular length to adapt to 
varying human heart (Anstadt, 1992).  One model is used for lengths less than 7.5cm, a 
second for lengths between 7.5-14cm, and a third for lengths greater than 14cm 
(Anstadt, 1992).  The lengths between the CorCap and the Anstadt cup do not 
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necessarily use the same references, so care must be taken when comparing dimensions 





Six different sizes of Acorn Cardiovascular‟s CorCap (Acorn, 2009) 










The Anstadt Cup is in need of significantly less device sizes than the CorCap or 
HeartNet because the inflatable nature of the Anstadt Cup does not require a precise fit 
as is required for the CSDs.  From this information it is hypothesized that the number of 
sizes needed for the AACSD for meeting the range of heart sizes expected is between 
three and six.  To determine the number of sizes needed for the AACSD additional 
testing of the embodied design would be required.  Testing must be done on a 
manufactured prototype to determine the effective range of heart sizes that a prototype 
can effectively provide adequate support and assist.  From this information, the 
appropriate number of models and sizing of each model to cover the entire range of 
hearts can be determined. 
Manufacturing of different sizes of the device is expected to be relatively 
straightforward, as the design embodiment process is readily transferable towards the 
development of multiple sizes in the product line.  The same methods of assembly and 
manufacture can be used for the development of each device size; only dimensions of 
the components must be varied.  For the passive bladder and the active bladder, the 
height and length of the films will need to be adjusted.  For the frame, the wire lengths 
must be varied.  The diameters of the internal hub components may not need to be 
adjusted as their vertical location within the passive bladder can be varied to achieve 
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different frame shapes close to the hubs; however if variable diameters of the hubs are 
needed then they can be readily manufactured in different sizes.  A benefit of 
manufacturing these hub components using RP is that the development of different sizes 
can be easily completed in a fraction of the time and cost in comparison to advanced 
manufacturing processes, like injection molding.  The assembly components can also be 
adjusted as needed.  For example, the hoop suture length may need to be adjusted to fit 
the new cup diameter.  Finally, the same port, port catheter, and valved catheter can be 
used for all of the cup configurations.   
 
15.3 Use of Engineering Plastics for the Hubs 
While the frame and bladder are made of durable engineering materials, the hubs 
were suggested to be made of resin that could be made through SLA.  If the development 
of a more durable rigid strong plastic with high fatigue strength properties is desired, 
then conventional manufacturing of engineering plastics is necessary.  Possible plastics 
for consideration include polyacetal and polysulfone.  Properties and applications of 





Properties and applications of material candidates for internal components 
a: (Teoh, Tang, and Hastings, 1998), b: (Kucklick, 2006), c: (Helmus and Hubbell, 1993)
 
  Properties Applications 
Polyacetal 
Outstanding creep and fatigue resistance, 
good toughness and impact resistance, 
excellent strength 
a
, low coefficient of 
friction, difficult to bond to, chemical 






injection port bodies 
Polysulfone 
Good rigidity, creep resistant, tough 
a
, high 
resistance to salt solutions, high strength 
b
 












          
 Both plastics have extensive and validated use in the medical device industry.  
Due to the low loads that the inner hubs will be experiencing, the excellent mechanical 
properties of each thermoplastic polymer are sufficient for the application.  However, the 
difficulty of bonding to polyacetal is well documented, and the need for the ability to 
bond the nitinol wire to the hubs makes this a significant concern.  For this reason 
polysulfone is the recommended material for the inner hub, outer hub, and sliding hub.  
Another important property of polysulfone is its high resistance to salt solutions, which 
is important since it will be housed internal to the saline filled passive bladder.  One 
available polysulfone is UDEL.  Select mechanical properties of UDEL polysulfone are 





Select mechanical properties of UDEL Polysulfone (Park and Lakes, 2007) 
Tensile strength 70 MPa 
Tensile modulus 2.52 GPa 
Elongation 50-100 % 





          
16. SUMMARY 
 
The design research performed is aimed toward the development of an AACSD 
concept suitable for a novel cup that can perform passive support and active assist on the 
heart and be deployed in a minimally invasive manner to meet the needs of CHF 
patients, and toward the embodiment for a manufactured design for further proof-of-
concept studies.  The AACSD is designed to encourage natural growth and remodeling 
of the heart that results in reduced EDV and increased stroke work, while weaning the 
heart off the device.  The research was successful in identifying a design for embodiment 
through classifying user needs, mapping user needs to design specifications for the 
device, using the design specifications for the generation of design concepts, and 
ultimately concept selection.  The research was also successful in identifying methods 
for embodying the design for manufacture.  Included are dimensions of the device, 
selection of a port and drive line for integration in the device, selection of materials for 
the device, a parts list, engineering drawings, and a FMEA for evaluation of the device.   
Further studies with the design will inevitably result in new criteria needed for 
the device and the identification of better techniques for accomplishing the criteria.  
However, the research provided herein uses a design process that encourages such 
iterative designing to ensure a quality system is maintained.  As changes are made to the 
design, the design process can be adapted and translated as needed to the new design.  
While changes are inevitable, it should be noted that the development of such a design 
plan for the design and embodiment of iterative designs is essential for verification and 
validation down the road to ensure the device has been thoroughly tested for 
performance and safety, and meets the needs of the user to provide a safer, more 
effective, and more natural CHF therapy.  
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APPENDIX A 
 
There are numerous methods available for determining the user needs of the 
market.  Methods available include direct methods that utilize user interaction, such as 
customer surveys or product demonstrations, while other methods are indirect and focus 
on research of the product and market.   Direct methods are most useful for consumer 
products and have the advantage of direct user feedback for determining the user needs; 
however such methods require extensive time, and often money, in contacting numerous 
users to gain an understanding of the user needs of the entire market and avoiding bias of 
a subset of the market.  Indirect methods lack the direct user interaction that is often 
desired for determining the user needs of consumer products; however indirect methods 
have the advantage of providing an objective and thorough analysis of the user needs 
without the need of contacting numerous users directly. 
One indirect method of determining user needs is to perform a contextual needs 
assessment (CNA).  A CNA consists of a listing of context factors that categorize user 
concerns of the product.  The response to the concerns is determined through research of 
unmet user needs from current therapies on the market, results of previous prototypes of 
the device, and animal studies.  The response to the concerns is then translated into the 
respective needs of the user for each particular context.  The CNA for determining the 
corresponding user needs for the device is shown in Table 27.  The particular template 
was adapted for specific use for this research from (Linsey, 2008).  The corresponding 
needs are used as the basis for the interpreted needs. 
 
 




        
 
Table 27 
Customer needs assessment.  Indicates contexts and needs for Product Application, Product Environment, and Customer Characteristics. 
# Context Factor Concerns Response to Concerns Corresponding Needs 
Application 
1 AACSD application What is the purpose of the AACSD?   
Limit the progression of congestive heart failure while 
promoting natural mechanics. 
reduce heart size, restore natural 
heart function 
2 AACSD function 
What functions should the AACSD 
provide? 
Provide passive support and active assist to a failing heart 
in a minimally invasive manner. 
reduce risks of implantation, restore 
natural heart function 
3 AACSD quality What quality of function is needed? 
High quality is needed to ensure that device does not 
damage heart or endanger patient. 
minimize risk of device failure, 
reduce risks of implantation, not 
detrimental to heart 
4 AACSD process 
What are the current therapies?  How will 
the AACSD differ?   
Current options include other invasive procedures that do 
not provide a natural recovery.  The product allows for a 
minimally invasive treatment for a more natural recovery. 
reduce risks of implantation, reduce 
heart size, restore natural heart 
motion 
5 AACSD frequency How often will the AACSD be used? 
Use will vary based on heart condition.  Passive support 
will be used continuously to gradually wean heart off 
device and active assist will be used only as needed in 
short intervals. 
adequate product lifetime, ease of 
access to device, ease of monitoring 
device, minimize risk of device 
failure 
6 AACSD duration How long will the AACSD be in use? 
Passive support will be used on the order of weeks.  
Active assist will be used on the order of minutes in short 
intervals as needed.   
adequate product lifetime, minimize 
risk of device failure, ease of 
monitoring device 
7 AACSD performance How will performance be measured? 
A statistically significant increase in cardiac output and 
reduction in overall heart volume.  
reduce heart size, increase cardiac 
performance 
8 AACSD ruggedness How roughly will product be handled? 
Device will be methodically collapsed prior to 
implantation. 
reduce risks of implantation, 
minimize risk of device failure 
9 User Condition What is the condition of the user? 
Patient is in a compromised state, and can only perform 
basic limited tasks. 
increase cardiac performance 
10 Sterilization 
How and where might the product be 
sterilized? 













        
 
Table 27 Continued 
# Context Factor Concerns Response to Concerns Corresponding Needs 
Environment 
11 AACSD surroundings 
Where and in what type of surroundings 
will product be used? 
Device will be implanted in a surgical environment.  
Once implanted, will be subject to the environment of the 
patient's body. 





What objects will the AACSD interact 
with? 
Device will interact with delivery system and external 
components. 
ease of operation 
13 Available space 
How much space is available for the 
AACSD? 
Device must fit in pericardial sac. ease of access to device 
14 Storage How will the AACSD be stored? AACSD will be stored in sterile packaging until needed.   device adequately stored 
15 Adjustments and monitoring 
How will adjustments and monitoring of the 
AACSD be done? 
Adjustments and monitoring will be performed by 
physician.   
ease of access to device, ease of 
monitoring, ease of operation 
16 Energy availability 
What is the availability of possible energy 
sources? 
Availability of fluid, pneumatic, and electric energy is 
readily available. 
ease of operation 
Customer Characteristics 
17 AACSD user 
Who will use the AACSD?  What user 
characteristics affect what the AACSD must 
be like? 
Physicians will choose to obtain for use by the patient.  
Device implantation and monitoring must be 
straightforward. 
ease of operation, ease of 
monitoring, reduce risks of 
implantation 
18 User experience level How skilled is the user with the task?  The users will be experienced physicians. 
ease of implantation, ease of 
operation 
19 
User tolerance  
for complexity 
What complexity level is allowed? 
Users are comfortable operating complex products, but 
concern is needed to make process as straightforward as 
possible to reduce patient risk. 
reduce risks of implantation 
20 Regulatory Concerns What regulations must the AACSD meet? Must meet FDA regulations. FDA approved  
21 Cost expectations 
What are the financial concerns for the 
AACSD? 
Due to limited options available to the patient and the 
availability of health insurance, cost is not a primary 
concern. 
FDA approved  
22 
Time expectations: 
implantation & operation 
How much time is the physician willing to 
spend implanting product?  To operate this 
product? 
Implantation time should be minimized as much as 
possible.  Length of operation times are not a primary 
concern. 
ease of implantation, adequate 
lifetime 
23 Safety and Risks 
What safety concerns does the patient have 
regarding the AACSD?  
Safety concerns are of the utmost importance.  The 
device should not inhibit cardiac function when not in 
use.  Adverse material interactions and infections need to 
be minimized. 
not detrimental to heart, reduce 
risks of infection, adequate lifetime, 
minimize risk of device failure 
24 AACSD lifetime What is the expected life of the AACSD? 
Device should last at least as long as the life expectancy 
of an end-stage heart patient, therefore, on the order of 
years. 
adequate product lifetime, minimize 
risk of device failure 
25 Selection for Use How will AACSD be selected for use? 
Physicians will take into account patient characteristics 
when deciding if the device is right for the patient. 




          
APPENDIX B 
 
 The first category is concepts for the passive and active bladders, as shown in 
Fig. 31.  These concepts describe possible bladder arrangements and alignments of the 
cup for both the active bladder and the passive bladder.  The vertical, curved, and helical 
concepts are composed of separate bladders that are circumferentially joined to create 
the cup shape.  The global bladder consists of a single bladder in the shape of the cup.  
The pocket bladder is sort of a hybrid, consisting of little bladders connected by a single 
network of channels in the cup.  The chamber concept is composed of four bladders, one 
over each heart chamber to allow for adjustments to be made on each individual bladder 

















Global Pocket Chamber 
Fig. 31.  Concepts generated for passive bladders and active bladders.  Concepts include: (a) Curved, (b) 




 The next category is the interface between the passive and active bladders.  This 
is shown in Fig. 32.  The bladders may be arranged in one layer to form a single 
component of the cup, or two layers to form inner and outer components of the cup. 
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Another method uses complete integration of the passive and active bladders.  This 
approach uses a single layer of bladders that perform both passive support and active 
assist.  The final concept is a detachable active bladder that can be removed from the 
patient when no longer needed.  Since the active assist is only needed initially this 
















Integrated Active Detachable 
Fig. 32.  Concepts generated for interface of passive and active bladders.  Concepts include:  (a) 2-Layer, 




 The next category, shown in Fig. 33, is concepts for the frame.  The frame is 
responsible for giving support to the device, expanding the device for deployment 
around the heart, and promoting proper kinematics of the cup in response to the applied 
loads of the heart.  The frame will be composed of metal wire.  The first concept is a 
petal frame.  The second is an offset petal frame that is similar to the petal frame, but the 
petals are tilted to change the direction of motion of the petal.  Next is a concept of using 
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braided wire to support the frame.  The net mesh concept consists of a wire array as a 
mesh to form the cup, similar to the Paracor HeartNet.  The modified petal consists of 
two sections; the lower section provides support while the upper section allows for the 
frame petals to rotate at a higher pivot point.  As the heart reduces in size, this allows for 
the frame to better envelope around the heart due the higher location of the pivot points.  
The helical frame consists of a wire rotating around the cup.  The branch concept uses 
multiple wires that come up from the base to the apex and then double back over 
themselves to terminate back at the base.  The final concept is a circumferential frame is 
composed of wires forming loops around the cup but is connected to each other around 





















Modified Petal Helical Branch Circumferential 
Fig. 33.  Concepts generated for the frame.  Concepts include: (a) Petal, (b) Offset Petal, (c) Braided, (d) 




The next category is the cup base, as shown in Fig. 34.   The regular frame base 
concept is composed of using the selected frame as the base, with no additional 
components.  The polymer ring base concept uses a polymer ring at the base that can 
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handle rotation, and is elastic to return the device to its original position.  The rotating 
base concept uses an inner ring and an outer ring that are free to rotate relative to each 
other. The next two concepts focus on reducing loads in line with the cup by dampening 
the loads from the tubing.  The first uses a fluid bladder at the cup base to act as a shock 
absorber, and the second uses a material damper to absorb the energy.  The material 
















Fluid Damper Material Damper  
Fig. 34.  Concepts generated for the cup base.  Concepts include:  (a) Regular Frame Base, (b) Polymer 




 The next step in the design process phase is to evaluate the concepts using a Pugh 
chart based on the design requirements previously determined.  The first Pugh chart is 
for the passive bladder, shown in Table 28.  The curved bladder was used as the datum 
for the Pugh chart.  Due to the similarities between the vertical and curved bladders, the 
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Pugh chart indicates that the two meet the criteria in a comparable manner.  The helical 
concept fared slightly better than the datum based on the helical shape of the bladders 
being able to handle the rotation of the cup more favorably.  The pocket bladders proved 
to be a poor concept variant and met the criteria worse than the datum in several 
categories due to its difficulty to manufacture and operate based on the level of intricacy 
needed for the concept.  The chamber concept likewise performed unfavorably 
compared to the datum.   With the ability to control each chamber bladder separately, the 
level of difficulty in making such a bladder and the tubing needed to implement such a 
bladder are too much.  The effect of the usefulness of this idea is negated by the passive 
bladder being a steady-state system, and in order to vary each bladder individually 
multiple ports would be needed.  The Pugh chart indicates the best concept is the global 
bladder.  The simplicity makes the design easier to manufacture, assemble, and operate.  





Passive bladder Pugh chart 
 
Candidate Concepts 
Criteria Curved Vertical Helical Global Pocket Chamber 
Ease in filling passive bladder 0 0 0 0 -1 0 
Ease in emptying passive bladder 0 0 0 0 -1 0 
Ability to obtain uniform pressure 0 0 0 1 0 0 
Ability to handle rotation 0 0 1 0 -1 0 
Amount of tubing needed 0 0 0 1 0 -1 
Avoid cavity obliteration 0 0 0 -1 1 0 
Manufacture and assembly 0 0 0 1 -1 -1 
Ease of deployment 0 0 0 0 0 0 
Amount of material/cost 0 0 0 0 -1 0 




The next Pugh chart, Table 29, shows the results for the active bladder.  The 
selection criteria for the active bladder is the same as for the passive bladder, however 
the rapid cycling of the active system can affect the concept variant‟s ability to satisfy 
the criteria differently than for the passive system.  Similar to the passive bladder, the 
curved, vertical, helical, and chamber concepts were comparable to the passive bladder 
scores.  The pocket configuration scored even less due to the rapid cycling needed to fill 
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and empty the bladders with each heart cycle and the pocket assembly inhibiting this 
rapid cycle.  The clear winner was again a global bladder.  In addition to its advantages 
discussed previously, the global bladder allows for less interference of air flow between 





Active bladder Pugh chart 
 
Candidate Concepts 
Criteria Curved Vertical Helical Global Pocket Chamber 
Ease in filling active bladder 0 0 0 1 -1 0 
Ease in emptying active bladder 0 0 0 1 -1 0 
Ability to obtain uniform pressure 0 0 0 1 -1 0 
Ability to handle rotation 0 0 1 0 -1 0 
Amount of tubing needed 0 0 0 1 0 -1 
Avoid cavity obliteration 0 0 0 -1 1 0 
Manufacture and assembly 0 0 0 1 -1 -1 
Ease of deployment 0 0 0 0 0 0 
Amount of material/Cost 0 0 0 0 -1 0 




 The passive and active bladder interface Pugh chart is shown in Table 30.  The 2-
layer concept was used as the datum.  The 1-layer concept compared favorably over the 
2-layer in that the device requires less volume and material, however this advantage is 
negated by the bladders potentially interfering with each other.  For example, an active 
bladder surrounded by passive bladders on either side may encounter too much 
resistance in filling.  Likewise the integrated concept provided advantages of reducing 
the volume and materials of the device; however the operation of a single integrated 
passive and active system is much more complex.  While the active detachable concept 
provides the benefit of removing part of the device once no longer needed, the ability to 
make such a design is much more difficult and the need for a second surgery to remove 
the cup is not worth the benefits.  Therefore, the selected concept of the passive and 
active interface is the 2-layer approach, with the passive bladder and active bladder each 





          
Table 30 




2-Layer 1-Layer Integrated 
Active 
Detachable 
Interference on each other 0 -1 -1 0 
Ease of assembly and manufacture 0 1 1 -1 
Obtaining uniform pressures 0 -1 0 0 
Ease of deployment 0 0 0 -1 
Ease of filling bladders 0 -1 -1 0 
Ease of emptying bladders 0 -1 -1 0 
Amount of material/cost 0 1 1 -1 




The Pugh chart for selecting the frame concept is shown in Table 31.  The petal 
concept was used as the datum.  The braided design did not offer much advantage, and 
would be more difficult to assemble.  The net mesh frame had several benefits in 
providing a mesh support that could adapt to the size of the heart; however the amount 
of wire needed in the design and concerns of it restricting the bladders outweighed the 
advantages.  The modified petal offered several benefits due to its ability to adapt to the 
heart, however the design is much more difficult to manufacture.  The helical design 
provides excellent structure for the cup; however, its structure is too constricting and 
would likely affect the performance of the cup.  The branched design is similar to the 
helical in that it is more favorable towards rotation; however, the design of the branches 
does not provide the same type of cup structure.  The circumferential frame had concerns 
with collapsibility and manufacture.  The offset petal scored favorably for its ability to 
handle the rotation of the heart and conform to the heart more favorably than the regular 












          
Table 31 











Helical Branch Circumferential  
Collapsibility 0 0 0 -1 -1 -1 0 -1 
Ability to flare 0 0 0 -1 1 -1 0 0 
Provide shape 0 0 0 1 1 1 -1 1 
Material and cost 0 -1 0 -1 -1 0 0 0 
Handle Rotation 0 1 0 0 0 1 1 0 
Damage to heart 0 0 0 0 0 0 0 0 
Conform to heart 0 1 -1 0 1 -1 0 0 
Manufacture and 
assembly 
0 0 -1 -1 -1 0 -1 -1 




 The cup base Pugh chart is shown in Table 32.  The regular wire frame base is 
used as the datum.  The polymer ring scored lower than the datum due its added cost and 
manufacturing concerns.  Also of concern is fatigue of the ring and it possibly restricting 
the motion of the cup, thereby placing unwanted loads on the heart that counteract the 
heart‟s natural rotation.  The fluid damper presented many problems that outweighed the 
risks of it dampening any motion of tubes in line with the cup.  The material damper 
likewise took up too much space and provided difficulty in designing and 
manufacturing.  The rotating base is the suggested design for the cup base due to its 


















Amount of material needed/cost 0 -1 -1 -1 -1 
Space taken up 0 0 0 -1 -1 
Reduces damage to heart 0 0 1 1 1 
Reduces coupling 0 0 1 0 1 
Ease of operation 0 0 0 -1 0 
Ease of deployment 0 0 0 0 0 
Ability to handle rotation 0 1 1 0 0 
Manufacture and assembly 0 -1 0 -1 -1 
Impact when null 0 0 0 0 0 
Collapsibility 0 0 0 0 0 
Σ 0 -1 2 -3 -1 
 
 








Select manufacturer specifications for candidate ports. 
 












































32/13.5 Plastic 12.5 Attachable
















27.2/15 Titanium 12.7 Attachable










31.7/14.5 Titanium & Silicone 12.7
Pre-attached or 
attachable

























31.5/15.3 Plastic & Silicone 12.5
Pre-attached or 
attachable




































          
Table 34 
Specifications of valved catheter candidates. 
























































Radiopaque Silicone 9.6 1.6 76 Both Open 
Radiopaque Silicone 6.6 1 75 Both Open 
Radiopaque Silicone (Groshong) 8 1.5 50 Attachable Valved 
Radiopaque ChronoFlex 
Polyurethane 8 1.6 61 Attachable Open 
Radiopaque ChronoFlex 
Polyurethane 6 1.3 75 Attachable Open 
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Fig. 38.  Sliding hub, with dimensions. 
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Fig. 40.  Bard Access M.R.I. Port, with dimensions.
 
 





   
 
 
Fig. 41. Bard Access Groshong valved catheter, with dimensions.
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